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macrocyclic conformations (i.e. stapling). Importantly, the incorporated s-tetrazine chromophore will
undergo photodisassociation upon absorp-tion of a photon permitting the release of the restricted
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In chapter one, we aimed to study a fundamental folding process known as the helix-coil transition by
phototriggering coupled with transient two-dimensional infrared spec-troscopy (2D IR). The s-tetrazine
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into peptides and proteins to staple and unstaple the confor-mations. Conditions for the introduction of s-
tetrazine into cysteine sulfhydryl groups of unprotected peptides conducted with aqueous biphasic
conditions, permitting the con-struction of macrocyclic peptides with a wide range of functionally and ring
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conformations were released photochemically to their thiocyanate counterparts, and in turn the resulting
thiocyanates removed to regenerate the native peptide. To the best of our knowledge s-tetrazine comprises the
first example of a readily removable peptide sta-ple. Finally, the stapling and unstapling protocol has been
extended to include thioredox-in as an example of a protein with an incorporated s-tetrazine construct that
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ABSTRACT 
 
STAPLING AND UNSTAPLING PEPTIDES AND PROTEINS  
WITH s-TETRAZINE 
Stephen P. Brown 
Professor Amos B. Smith, III 
 
This thesis will focus on the design, synthesis, and validation of synthetic techniques to 
introduce s-tetrazine into peptides and proteins. The s-tetrazine molecule is effective for 
restricting peptides/proteins to macrocyclic conformations (i.e. stapling). Importantly, the 
incorporated s-tetrazine chromophore will undergo photodisassociation upon absorption of 
a photon permitting the release of the restricted conformations (i.e. unstapling). 
In chapter one, we aimed to study a fundamental folding process known as the helix-
coil transition by phototriggering coupled with transient two-dimensional infrared spec-
troscopy (2D IR). The s-tetrazine molecule possesses the photochemical properties of an 
ideal phototrigger, as such, s-tetrazine was employed towards the development of tech-
niques capable of capturing the fastest structural transitions of biomolecules with both high 
spatial and high temporal resolution. Tripeptide linchpins, containing the s-tetrazine pho-
totrigger, were prepared by solid-phase peptide synthesis. The latter were then employed 
toward the construction kinked helices near equilibrium via a fragment coupling procedure. 
The relaxation of the kinked helical structures were observed by pump/probe transient 2D 
IR spectroscopy. 
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In chapter two, new synthetic protocols have been developed and validated for the in-
troduction of s-tetrazine into peptides and proteins to staple and unstaple the confor-
mations. Conditions for the introduction of s-tetrazine into cysteine sulfhydryl groups of 
unprotected peptides conducted with aqueous biphasic conditions, permitting the construc-
tion of macrocyclic peptides with a wide range of functionally and ring topology, bridging 
from one to 27 amino acid residues adjoining the cysteines. Importantly, the stapled con-
formations were released photochemically to their thiocyanate counterparts, and in turn the 
resulting thiocyanates removed to regenerate the native peptide. To the best of our 
knowledge s-tetrazine comprises the first example of a readily removable peptide staple. 
Finally, the stapling and unstapling protocol has been extended to include thioredoxin as 
an example of a protein with an incorporated s-tetrazine construct that can also serve a 
useful role in conjugation strategies. 
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CHAPTER 1. Development of a Phototriggering Strategy to Measure 
the Ultrafast Non-Equilibrium Dynamics of Peptides  
 
Introduction 
Proteins and peptides, dynamic entities comprised of amino acids linked together into a 
linear chain, are responsible for a wide array of functions in biochemistry.1-4 These chains 
of amino acids ultimately fold into three-dimensional structures, exploiting conformational 
changes and transient molecular interactions, which in turn, determines the underlying 
mechanism of a protein’s biological function. The early kinetic events that govern confor-
mational dynamics in peptides and proteins are critical for the development and refinement 
of model systems that relate dynamic structure to the observed biological function.5-7 X-
ray crystallography8-9 and nuclear magnetic resonance measurements10 can achieve atomic 
resolution static structures, however these techniques do not provide information of the 
transient, non-equilibrium structures. Techniques such as infrared (IR) spectroscopy, Ra-
men spectroscopy and fluorescence resonance energy transfer (FRET) have also been de-
veloped to capture the structural transitions of biomolecules. However, none of the existing 
methods are capable of following the ultrafast folding dynamics with both high spatial and 
temporal resolution.11 The development of methods to achieve atomic resolution transient 
structures within the ultrafast time regime holds the promise towards understanding the 
process that peptides and proteins undergo to self-assemble into well-ordered three-dimen-
sional structures and in turn reveal significant insight into protein folding diseases. 
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Exploration of the Helix-Coil Transition 
With the goal of developing a technique capable of capturing the fastest structural tran-
sitions of biomolecules with both high spatial and high temporal resolution, we began with 
a basic folding process. The helix-coil transition is a fundamental folding transition com-
monly used by peptides and proteins. The rates for the helix-coil folding processes had not 
previously been measured, but had been estimated to be on the order of pico- to nanosec-
onds with computer simulated values conflicting by more than two-orders of magnitude.12-
14 To achieve our goals, a successful method would require both structurally defined start-
ing and end points in the folding process for spatial control, coupled with a technique ca-
pable of observing the backbone folding process on an ultrafast timescale. 
Two-Dimensional Infrared Spectroscopy 
Two-dimensional infrared spectroscopy (2D IR) has been developed and refined by 
Hochstrasser to monitor the ultrafast conformational changes in peptides.15 In the broadest 
sense 2D IR permits a fourier transform infrared (FTIR) spectrum to be transposed onto 
two axes (Figure 1.1).16 This technique uses a series of pulses which are separated by  
 
Figure 1.1. Two-Dimensional Infrared Spectroscopy Technique 
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controllable time delays to generate an IR spectrum containing additional cross-peaks. The 
cross-peaks found within the spectrum are related to the vibrational coupling between two 
similar harmonic oscillators. The intensity of the signals arising from the vibrational cou-
pling are sensitive to both distance and orientation and in the cases of amide coupling 
within a peptide, the signals can be translated into phi/psi angles.17-18 The two-dimensional 
IR technique is capable of operating on a picosecond timescale; as such, multiple snapshots 
can be collected and translated into dynamic information as to how the peptide folding 
process is progressing in solution at specific time points. 
Phototriggering: A Technique to Explore Peptide/Protein Conformational 
Change 
 
Phototriggering comprises a method that builds a macrocyclic constraint into the peptide 
structure such that the constrained peptide takes on a new ground state and confines the 
peptide into a narrow distribution of conformations. Additionally, the macrocyclic con-
straint must be photolabile such that laser-induced photolysis will break the constraint on 
an ultrafast timescale permitting the peptide to refold to new ground state configurations. 
One of the earliest examples of phototriggering was conducted by Hochstrasser and 
DeGrado.19-20 These efforts employed bis-aryl disulfides to initiate the conformational 
change in the dynamics of peptides. The bis-aryl disulfide phototrigger underwent photol-
ysis at 270 nm to sever the disulfide bond and expose two sulfur-centered radicals, permit-
ting the peptide to refold into a new configuration (Figure 1.2).19 A number of challenges 
were presented in this experiment. First the hydrophobic nature of the aryl groups could 
affect the folding process. Second, the sulfur centered radicals can react with the 
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Figure 1.2. Disulfide Bond Photolysis to Initiate Conformational Dynamics 
 
peptide and/or undergo geminate recombination. Lastly, the 270 nm wavelength used to 
sever the disulfide bond is not compatible with tryptophan and tyrosine residues in the 
peptide. The information gained from these experiments were used by Hochstrasser and 
Smith to design an improved phototrigger. The design of an optimal phototrigger for the 
study of ultrafast folding processes would possess the following properties: 1) fragment 
rapidly on the femto- to picosecond time scale; 2) undergo fragmentation with a high pho-
toproduct yield upon flash photolysis; 3) constrain the peptide within a narrow, well-de-
fined distribution of conformations; 4) produce photofragmentation products that are non-
reactive and do not interfere with the conformational changes or the monitoring techniques; 
and 5) undergo fragmentation with visible wavelengths to ensure maximum biocompati-
bility.21 
Early Work on s-Tetrazine Photofragmentation 
The s-tetrazine molecule possesses the photochemical properties of an ideal phototrig-
ger. The photofragmentation of s-tetrazine was initially described by Smith and 
Hochstrasser.22 Molecules of s-tetrazine were shown to undergo absorption of an ultravio-
let (UV) photon at 327 nm to generate an excited state that collapses rapidly to form two 
Reactions with Sidechains
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nitriles and nitrogen gas (Figure 1.3). Further experiments at low temperature revealed, 
that it was possible to use crystals of s-tetrazine in natural isotope abundance and tune a 
laser to selectively photolyze all of the lighter isotope material, leaving an enriched  
 
 
Figure 1.3. Photofragmentation of s-Tetrazine 
 
sample with the heavier isotopes.23-25 This experiment demonstrated that the s-tetrazine 
photolysis reaction mechanism did not contain radical intermediates. Now, given the fa-
vorable photochemical properties of s-tetrazine, the question arises; how to introduce te-
trazine into peptides? The effect of carbon substituents at the 3,6-positions were shown to 
increase the number of vibrational modes for relaxation of the tetrazine excited state, and 
as a result, increased the fluorescent lifetimes leading to poor photoproduct yields. The 
effect of a heavy atom, such as sulfur, however had not been examined and as such might 
help retain the vibrational energy within the excited state of s-tetrazine to promote a better 
photoproduct yield.  
Synthesis of Dichlorotetrazine 
 
To address the question, could sulfur substitution on s-tetrazine improve the photochem-
ical outcome, we turned to dichlorotetrazine (5, Scheme 1.1). The synthesis of dichloro-
tetrazine had previously been described,26-27 beginning from guanidine hydrochloride and 
heating at reflux with hydrazine precipitated triaminoguanidine hydrochloride (1) as a 
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white amorphous solid (mp 233-237 ºC). The solid 1 was then reacted with two equivalents 
of acetylacetone which spontaneously formed a bis-pyrazole hydrazine intermediate. Heat-
ing the latter leads to an intermediate which forms a dimer and precipitated as a light yellow 
amorphous solid of dihydrotetrazine 2 (mp 147-149 ºC). After the oxidation of 2 with NO2 
gas, the red the tetrazine core 3 (mp 224-226 ºC) is obtained as a solid following evapora-
tion of the solvent. The pyrazoles of 3 are then displaced with hydrazine resulting in the 
 
 
Scheme 1.1. The Synthesis of Dichlorotetrazine 
precipitation of dihydrazinyl-s-tetrazine (4) as a fine, amorphous powder. Notably, 4 was 
tested by differential scanning calorimetry and thermogravimetric analysis (DSC-TGA) 
and shown to undergo an exothermic decomposition above 120 ºC in the presence of air; 
CAUTION: must be used when forming and isolating this compound.  Finally, 4 was ox-
idized with trichloroisocyanuric acid to furnish dichlorotetrazine (5) as a red, solid (m.p. 
147-150 ºC) in a 41% yield over the five steps. 
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Preparation of Bis-Cysteine-S,S-Tetrazine and Photophysical Evaluation 
 
To prepare a 3,6-sulfur substituted s-tetrazine, a graduate student Joel Courter initially 
treated dichlorotetrazine (5) with two equivalents of cysteine 6, protected as the methyl 
ester and acetyl amide, in pyridine and methylene chloride to furnish the model S,S-te-
trazine compound 7 (Scheme 1.2).28 Photochemical evaluation of 7 was then conducted 
 
 
Scheme 1.2. Synthesis and Photolysis of Bis-Cysteine-S,S-Tetrazine 
 
via flash photolysis coupled with transient IR spectroscopy. The experiment consisted of a 
single flash pulse at 410 nm to release the s-tetrazine constraint and the evolution of the 
thiocyanate absorbance was observed at 2163 cm-1 by transient IR on the picosecond time-
scale (Figure 1.3).29 The thiocyanate transient absorbance growth of 8 was plotted at spe-
cific time points to determine the formation of thiocyanate time constant of 177 ps with an 
11% yield of 8. Experiments conducted at 355 nm flash pulse doubled the yield to 22%, 
thus the dicysteine S,S-tetrazine 7 represented a new class of compounds that held consid-
erable potential as an ultrafast phototrigger. 
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Figure 1.3. Photochemical Evaluation of the S,S-Tetrazine Phototrigger 
 
Preparation of a S,S-Tetrazine Kinked Helix Near Equilibrium 
To achieve the goal of inserting the s-tetrazine phototrigger within larger peptides to 
explore the helix-coil transition, studies were initiated to construct peptides containing the 
s-tetrazine constraint within the alanine-rich peptide 9 (Figure 1.4), a system which adopts  
 
Figure 1.4. Design of a Helical System Perturbed by the s-Tetrazine Chromophore 
 
B. Transient IR of Thiocyanate Vibrational Mode
C. Rate of Thiocyanate Formation
A. Flash Photolysis of S,S-Tetrazine
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an -helical structure in the ground state. Reasoning that the introduction of the s-tetrazine 
moiety within the middle of a 24-residue peptide via insertion between two cysteine resi-
dues would permit both the N- and C-terminal segments of the peptide to adopt an -helical 
conformation, while the amino acids near the cysteine residues would form a kinked con-
formation due to the geometric constraint enforced by the incorporated s-tetrazine photo-
trigger.  Photolysis would then release the constraint imposed s-tetrazine phototrigger, per-
mitting the peptide to undergo refolding, the exact nature of which had not previously been 
explored. To this end, the two alanine residues at the tenth and twelfth positions were se-
lected to be replaced with the cysteine residues required to incorporate the s-tetrazine, giv-
ing rise to 10 (Figure 1.4) as the synthetic target.   
Synthesis of Tripeptide Linchpins Containing s-Tetrazine  
 
The first attempt to construct 10, conducted by postdoctoral fellow Mohannad Abdo, 
entailed the solid-phase synthesis of the full-length peptide, followed by selective removal 
of the cysteine protection groups and addition of dichlorotetrazine. After cleavage from the 
resin support, a complex mixture was observed and no product was obtained from the re-
action. Undeterred, we identified that dichlorotetrazine could be introduced into shorter 
tripeptides employing solid-phase peptide synthesis.30 To this end, tripeptides were pre-
pared by solid-phase peptide synthesis containing the two requisite cysteine residues 
(CAC) with the sulfhydryls protected with mono-methoxytrityl (Mmt) groups (Scheme 
1.3). Suitable conditions for the selective deprotection of the Mmt, specifically 2% tri-
fluoroacetic acid provided the free sulfhydryls without cleaving the peptide from the solid-
support.  
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Scheme 1.3. Solid-Phase Synthesis of S,S-Tetrazine Containing Tripeptide Linchpins  
 
The sulfhydryls were next reacted with dichlorotetrazine, and following cleavage from 
resin, the macrocycles (11 and 12) were obtained.  To test the photochemical ring opening 
of the incorporated s-tetrazine constraint, peptide 12 was irradiated in a methanol solution 
under UV-A lamps in a Rayonet photoreactor to provide near quantitative conversion to 
the dithiocyanate peptide 13 (Scheme 1.3). A series of natural amino acids were incorpo-
rated within the tripeptide and were evaluated to demonstrate the compatibility of other 
side chains with the developed solid-phase peptide synthesis conditions. To this end pep-
tides 14-20 were prepared by the same method (Scheme 1.4). Only arginine displayed ad-
ditional reactivity after removal of the guanidium protection group. With the ability to pre-
pare various s-tetrazine peptide macrocycles now in hand, this synthetic method can also 
be employed to introduce isotope labels into the peptide backbone. The isotope-enriched 
amino acids were incorporated into the peptide sequence by the same solid-phase peptide 
synthesis protocol; dichlorotetrazine insertion gave 21 and 22 (Scheme 1.4). Importantly, 
the IR signals of the isotopically enriched 13C=18O amide peptides 21-22 are shifted out of 
the main amide I band region, given the change in the zero point of the molecular vibration, 
11 
 
 
Scheme 1.4. Tetrazine Tripeptide Linchpins Prepared by Solid-Phase Synthesis 
 
 
 
Figure 1.5. Infrared Shift of Isotopically Labeled Amides 
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perturb thephotolysisof theelectron-deficient S,S-tetrazine
chromophore.
To monitor structural transitions on a fast time scale
employing 2D-IR, differentiation of the amide I IR
stretching modes of the diverse peptide carbonyls would
be required.12 To this end, tripeptides 4l,m and 7 were
prepared (Figure 4), wherein the alanine and/or cysteine
amino acid carbonylswerelabeledwith 13Cor correspond-
ing13C/18O, thelatter preparedbyH2
18Oexchange13of the
13C-amino acid (see SI). Tripeptides 4l,m were then pre-
pared according to the previously developed solid-phase
conditionsemploying theisotopically labeled amino acids.
A modification to thisprotocol was required to construct
tripeptide 7, as the 18O enrichment procedure proved
incompatible with the para-monomethoxytrityl sulfur-
protected cysteine. Pleasingly employing thethio-tert-butyl
sulfur protected amino acid during the 18O exchange14
followed by solid-phase peptide synthesis proved effective.
Sequential removal of the cysteine protecting groups with
tributylphospineand TFA prior to insertion of thetetrazine
moiety permitted preparation of tripeptide 7.
IR analysisof theisotopically labeled tripeptidesrevealed
that the 13C/18O and 13C amino acid amide carbonyl
stretching bandsareshifted by ∼60 and ∼30 cm 1, respec-
tively,with thedoubly labeledpeak appearingat∼1590cm 1,
well separated from themain amide I band (Figure5). The
stretching frequency of thesingly labeled carbonyl, however,
remained somewhat buried in themain band.
Following thesuccessful preparation of the4a mseries
of tetrazine tripeptide linchpins, designated as (i, iþ 2)
with regard to separation of Cys residues, wenext sought
to study larger macrocyclic congeners that inscribe the
tetrazine ring. Standard Fmoc-based solid-phase peptide
synthesiswasemployed to construct the(i, iþ 3) and (i, iþ 4)
target peptides 9a,b and 9c respectively (Figure 6). With
these model linchpins in hand, the photofragmentation
reaction wasagain investigated. Nanosecond flash photo-
lysis15 experiments revealed a dependence of the photo-
chemical yield on the size of themacrocyclic peptide con-
strained by the S,S-tetrazine. Peptide 4c, with an (i, iþ 2)
relationship between the Cys residues, afford the highest
photoproduct yield upon flash photolysis (> 25%). The
(i, iþ 3) relationship in 9b led to adecreasein photoproduct
to > 15%;afurther decreaseto∼10% wasobserved for the
(i, iþ 4) peptide 9c. The observed photochemical yield
dependence is likely related to the conformational strain
exerted by the peptides on the S,S-tetrazine ring. Impor-
tantly thephotochemical yieldsaresufficient that popula-
tion changes are observable by 2D IR, while adequate
intact linchpin ismaintained to enable spectroscopic data
to beaccumulated over an extended period of time.
Figure 3. Tetrazine tripeptides synthesized in 7 30% overall
yield with the exception of 4k which undergoes decomposition
upon purification.
Figure 4. Isotopically labeled S,S-tetrazine containing tripep-
tide units with doubly labeled carbonyls highlighted in yellow
and singly labeled in green.
Figure 5. Infrared spectra (1550 1770 cm 1) of 4a (red), 4l
(green), and 7 (black) recorded in CD3OD.
(12) (a) Torres, J.; Adams, P. D.; Arkin, I . T. J. Mol. Biol. 2000, 300,
677–685. (b) Fang, C.; Wang, J.; Charnley, A. K .; Barber-Armstrong,
W.; Smith, A. B.; Decatur, S.M .; Hochstrasser, R.M .Chem. Phys. Lett.
2003, 382, 586–592. (c) Fang, C.; Wang, J.; K im, Y. S.; Charnley, A. K .;
Barber-Armst rong, W.; Smith, A. B.; Decatur, S. M .; Hochstrasser,
R. M . J. Phys. Chem. B 2004, 108, 10415–10427. (d) Fang, C.;
Hochstrasser, R. M . J. Phys. Chem. B 2005, 109, 18652–18663.
(13) Marecek, B.; Song, B.; Brewer, S.; Belyea, J.; Dyer, R. B.;
Raleigh, D. P. Org. Lett. 2007, 9, 4935–4937.
(14) Gormer, K .; Waldmann, H.; Triola, G. J. Org. Chem. 2010, 75,
1811–1813.
(15) Papp, S.; Vanderkooi, J. M .; Owen, C. S.; Holtom, G. R.;
Phillips, C. M . Biophys. J. 1990, 50, 177–186.
12 
 
and can thus be observed independently from the rest of the peptide backbone (Figure 1.5). 
The isotope labeling feature permits the monitoring of picosecond structural transitions 
within the amide backbone by 2D IR without interference from the remaining amide sig-
nals of 10 following photochemical release. 
A Solution-Phase Fragment Coupling Strategy to Access a Kinked Helix (10) 
 
To prepare kinked helix 10 from the tripeptide linchpins (Figure 1.6), a solution-phase 
fragment union strategy was developed.31 This approach first required an orthogonal pro-
tection group strategy to differentiate the N-terminus of the linchpin 11 from the lysine 
side-chains of either fragment. The Boc- protection group and the removal thereof was 
demonstrated to be compatible with the tetrazine ring during the synthesis of the linchpins.  
 
Figure 1.6. Retrosynthesis of a Kinked Helix 10 Arising From a Three-Fragment Union 
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Evaluation of known deprotection conditions that are orthogonal to Boc were not compat-
ible with the S,S-tetrazine phototrigger. Notably, the basic conditions used to remove the 
Fmoc-group were found to react with the tetrazine peptides. Interesting reactivity with the 
tetrazine chromophore was observed upon application of reductive conditions employed to 
remove the Cbz-protection group in peptide 7. Importantly, treatment with Pd/C and hy-
drogen gas led to the reduction of the s-tetrazine ring to the dihydrotetrazine congener 23. 
When the colorless solution of the reduced product 23 was exposed to air, 23 underwent 
oxidation back to the red starting material 7 (Scheme 1.5).  
 
 
Scheme 1.5. Reduction of the s-Tetrazine Chromophore 
 
To test the conditions for Cbz removal, model peptide 24 was prepared. Treatment of 
24 under the identical conditions outlined in Scheme 1.5, reduced the s-tetrazine ring; but 
did not lead to efficient removal of the Cbz group. Forging a new strategy, Cbz is known  
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Scheme 1.6. Benzyl Carbamate Removal with Concentrated Trifluoroacetic Acid 
 
to be mildly unstable under strongly acidic conditions. To this end, stirring 24 in a solution 
of neat TFA (Scheme 1.6) was found to drive off carbon dioxide over the course of 24 hours 
to furnish 25 with efficient removal of the Cbz group and importantly without affecting the 
tetrazine chromophore. 
Turning next to the construction of the full-length peptide 10 containing the s-tetrazine 
ring, a solution-phase fragment union protocol was developed by post-doctoral fellow Mo-
hannad Abdo. With the use of the Cbz protecting group validated, the synthesis of the target 
10 was planned to arise via union of three fragments 26, 27 and 28 (Scheme 1.7).  The 
appropriate linchpin 26 was prepared via Boc protection of the N-terminus of 11 (from 
Scheme 1.3). The protected C- and N-terminal peptide fragments 27 and 28 in turn were  
  
 
Scheme 1.7. Solution-Phase Fragment Coupling of the s-Tetrazine Kinked Helix 10 
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constructed via solid-phase peptide synthesis employing N-methyl indole and 2-chlo-
rotrityl resins, respectively. After activation of linchpin 26 with the coupling agent, HBTU, 
the free amine of peptide 27 was coupled. Then, following purification and removal of the 
Boc protecting group, the resulting peptide was attached to the activated peptide fragment 
28. Global deprotection was then achieved by treatment with neat TFA to furnish target 
peptide 10 in an 11% yield over four steps after final HPLC purification (Scheme 1.7).  
To monitor the picosecond structural transitions within specific regions of the amide 
backbone by 2D IR following the photochemical release of s-tetrazine within 10, the amide 
stretching modes at specific locations along the peptide construct required differentiation 
by isotopic editing of the amides.  Specifically, we sought to incorporate the 13C=18O dou-
ble label at three defined positions along the peptide backbone.  The solution phase  
  
 
Figure 1.7. Isotopically Enriched Amides Within the Constrained Helices 
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fragment coupling strategy (Scheme 1.7) was used to prepare labeled peptides 29-31 (Fig-
ure 1.7). Peptide 30 would permit measurement of the kinked region while the backbone 
dynamics distal to the s-tetrazine phototrigger could be monitored through the two 
13C=18O-Ala units introduced within 29 or 31 specifically at amino acid locations 5-6 and 
17-18, respectively.  
2D IR Observation of Non-Equilibrium Folding Dynamics of a Kinked Helix 
 
The isotopically enriched helical peptides 29-31, constrained with the tetrazine photo-
triggering cross-link, were then used to explore the ultrafast, non-equilibrium folding dy-
namics of the kinked helix.32 Transient 2D IR spectroscopy was used to record structural 
snapshots of the bond distances and bond angles during formation of a single helical turn 
of the kinked helix upon photorelease of the tetrazine chromophore (Figure 1.8). The re-
sults with the isotopically labeled variant peptides 29-31 proved structurally distinct. When 
10 is isotopically edited with 13C=18O at residues Cys10 and Ala11 (i.e.30), both 
 
 
Figure 1.8. Non-Equilibrium Folding Dynamics Observed  
 
amide backbone vibrations are isotopically down-shifted 60 cm–1, which strongly reduces 
their coupling with those of the other carbonyls. The location, polarization, and line width 
S,S-Tetrazine
Photolysis
Complete in
< 67 ps 2D-IR probe
λ = 355 nm
700 fs pulse
Time
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of the isotopically shifted amide I band was then used to determine structural parameters 
in two picosecond snapshots, recorded over a nanosecond range of delays. To examine the 
site-specific structural changes upon photorelease, the two labeled peptides (29 and 31) 
were also examined. The amide I modes involving 29 and 31 each with a pair of residues 
spatially separated by approximately one helix turn from the kink revealed equivalent di-
agonal 2D IR trace spectra through all optical delay times, thereby implying that these 
residues do not undergo any significant structural change as a result of the photolysis.  On 
the other hand, the transient 2D IR spectrum of peptide 30 containing the labeled pair 
within the s-tetrazine distorted region, exhibits very different spectra and responses to pho-
tolysis.  
Specifically, the isotopically labeled region of 30, located around 1,600 cm–1, exhibits 
significant photolysis-induced changes in peak position and spectral width, which are most 
evident from the 2D IR diagonal traces. A frequency upshift of 7.5 cm–1 occurs over the 
first 300 ps after photolysis of 30, followed by a slight decrease to a fixed value (3 cm–1 
up-shifted) after 500 ps. The 2D IR spectral width of the diagonal 2D IR traces of this band 
increases by 5 cm–1 from the starting constrained configuration and then decreases until 
about 500 ps delay, whereupon a constant value is reached. The spectral width was fit to 
exponential decay with a time constant of 97 ± 7 ps indicating rotation about the psi angle 
to recover the helical structure. 
In summary, the design, synthesis and validation of peptides containing the s-tetrazine 
phototrigger in conjunction with 2D IR has permitted acquisition of the non-equilibrium 
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picosecond snapshots of helix relaxation. The constrained peptide 10 is believed to be lo-
cated somewhere on the downhill side of the free energy barrier towards the complete helix. 
Upon release of the constraint, the 2D IR spectra provided a glimpse into the conforma-
tional reorganization that occurs as the peptide proceeds toward equilibrium. These exper-
iments reveal key motions along the folding coordinate as the peptide reorganized toward 
the full α-helical conformation which importantly does not involve movements that push 
the kink along the chain toward the ends of the peptide. Moreover, the peptide also does 
not irreversibly unfold before proceeding toward the native helical conformation. Rather,  
the central region, where the small perturbation to the helical structure had been enforced 
by the constraint undergoes a local structural change following photorelease. The data col-
lected during the acquisition permits the visualization of the fastest structural changes for 
10, as the peptide proceeds toward the equilibrium ensemble in response to release of the 
phototrigger. Although the propagation times for helices have been estimated from exper-
iments to be on the order of tens of nanoseconds, the structural movements observed in 
these experiments suggest that propagation times after nucleation are on the order of hun-
dreds of picoseconds. Moreover, the simulated equilibrium time autocorrelations of the 
angle between the dipoles, the distance between the two dipoles, and the dihedral angles 
all agree well with the observed parameters, suggesting the conformational kinetics are 
well described by linear response theory.33 
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Experimental for Chapter 1 
 
Reaction Equipment. Solid-phase syntheses were carried out in peptide synthesis reaction 
vessels (25 or 50 mL) with coarse porosity fritted glass support and Teflon stopcocks. Pho-
tolysis experiments were performed in a RayonetTM Srinivasan-Griffin Photoreactor (The 
Southern New England Ultraviolet Company) using either UV-A lamps (part # LZC-UVA) 
or UV-B lamps (part # LZC-UVB) purchased from Luzchem.  
Chromatography. Prep-scale reverse-phase chromatography was conducted with a Gilson 
215 liquid handler/injector fitted with Gilson 333/334 binary HPLC pumps and UV/vis 
dual wavelength detector (model 156) and Trilution software. The chromatographies were 
carried out on a Waters XBridge Prep BEH 130 C18 5µm OBD 19 × 100mm column (part 
# 186003587). The eluent was acetonitrile (HPLC grade) and Millipore water with 0.1% 
trifluoroacetic acid buffer unless otherwise noted and gradients specific to the compound. 
Instruments Used for Spectral Data. 1H NMR, 13C NMR and 2D NMR spectra were 
recorded on a Bruker Avance III equipped with either a 5 mm dual inverse probe or 5 mm 
DCH CryoProbe. The analytical LC-MS analyses were conducted using a Waters 2767 
sample manager, consisting of a Waters 2525 binary gradient HPLC connected to a diode 
array detector and a Waters Micromass ZQ mass spectrometer with electro-spray ioniza-
tion. The LC-MS samples were analyzed as solutions in water or acetonitrile, prepared at 
0.15 – 0.20 mg/mL concentration. The LC-MS chromatography was carried out on an At-
lantis–C18 column (4.6 ×50 mm; 5 µm) with linear gradients of 0.05% formic acid in ac-
etonitrile and 0.05% formic acid water. High resolution mass spectrometry was obtained 
22 
 
on Waters LC-TOF mass spectrometer (model LCT-XE Premier) using electrospray ioni-
zation in positive or negative mode, depending upon the analyte. MALDI-MS spectra were 
collected with a Bruker Ultraflex III TOF/TOF matrix-assisted laser desorption/ionization 
mass spectrometer. All FTIR spectra were taken on a Nicolet 6700 FTIR spectrometer or 
PerkinElmer FTIR (model Spectrum BX).  
 
Triaminoguanidine hydrochloride (1). A 250 mL round bottom flask was charged with 
guanidine hydrochloride (14.70 g, 153.9 mmol) and suspended in 1,4-dioxane (80 mL). 
With magnetic stirring, hydrazine hydrate (25.2 mL, 508 mmol, 3.3 equiv) was added, after 
one minute, the solid had dissolved and the solution was refluxed for 2.0 hours during 
which time a white, solid precipitated. The contents were cooled to ambient temperature, 
vacuum filtered, and the solid washed with 1,4-dioxane (2 × 50 mL). The solid was dried 
in vacuo for 16 hours to yield 20.76 g (96%) of triaminoguanidine hydrochloride, as a 
crystalline white solid. 13C NMR (126MHz, D2O) δ = 159.7. 
 
A 1L, three necked flask was set-up with a reflux column and mechanical stirred. To the 
flask was added triaminoguanidine hydrochloride (14.06 g, 100.0 mmol) and dissolved in 
water (150 mL). Next, with mechanical stirring, acetylacetone (20.0 g, 200 mmol, 2 equiv) 
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was added dropwise from an additional funnel at a rate such that the exothermic reaction 
did not rise above ca.40 oC. After complete addition of the reagent, the solution was stirred 
at ambient temperature for 15 minutes and then heated to 80 oC for 3.5 hours during which 
time a light yellow solid formed and the solution turned dark orange. The contents were 
diluted with water (100 mL) then cooled to ca. 5 oC, the solid was collected by vacuum 
filtration and washed with ice water (3 × 100 mL) until the orange color was removed. The 
material was dried in vacuo for 16 hours to yield 10.00 g (74%) of bis-dimethylpyrrazol-
yldihydrotetrazine as faint yellow, amorphous powder. 1H NMR (500MHz, CDCl3) δ = 
8.07 (s, 2 H), 5.96 (s, 2H), 2.48 (s, 6 H), 2.21 (s, 6 H). 13C NMR (126MHz, CDCl3) δ = 
150.1, 145.9, 142.4, 110.0, 13.9, 13.6. 
 
A 125 mL Erlenmeyer flask was charged with bis-dimethylpyrrazolyldihydrotetrazine 
(10.00 g, 36.7 mmol) and dissolved in CHCl3 (75 mL) then cooled to 0
oC in an ice bath. 
Next, NO2 gas was generated by dissolving, in portions, copper wire (4.66 g, 73.4 mmol, 
2 equiv) in concentrated nitric acid (50 mL) contained in a separate Erlenmeyer flask. The 
red gas that evolved was pushed with nitrogen gas, through glass tubing and bubbled 
through the chloroform solution which turned dark red upon addition, the reaction was 
continued until the solution became saturated with NO2 evident by the red gas evolving 
from the chloroform solution (ca. 3 min). The solution was transferred to a separatory fun-
nel washed with saturated NaHCO3 (3 × 25 mL) followed by brine (2 × 25 mL) and dried 
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over MgSO4. The filtrate was stripped under reduced pressure to yield 9.72 g (98%) of bis-
dimethylpyrrazolyltetrazine a red, amorphous powder. 1H NMR (500MHz, CDCl3) δ = 
6.16 (s, 2 H), 2.68 (s, 6 H), 2.36 (s, 6 H). 13C NMR (126MHz, CDCl3) δ = 159.4, 154.5, 
143.8, 112.0, 14.7, 13.9. 
 
CAUTION: The dihydrazinyltetrazine product was found to undergo exothermic de-
composition above 120 oC when analyzed by DSC-TGA under air and ramping the 
temperature at 5o/minute. No decomposition was observed when dihydrazinylte-
trazine was held at 80oC under air for 60 minutes. As a precaution an inert atmos-
phere is highly recommended to prevent any oxidation during the course of the reac-
tion. 
Dihydrazinyltetrazine (4). A 250 mL, two-necked flask was charged with bis-dime-
thylpyrrazolyltetrazine (9.72 g, 36.0 mmol) and suspended in acetonitrile (75 mL), a reflux 
condenser was attached and the contents placed under a nitrogen atmosphere. Next, hydra-
zine hydrate (3.57 mL, 72.0 mmol, 2.05 equiv) was added neat with magnetic stirring. The 
flask was placed in an oil bath, pre-heated to 70 oC for 75 minutes, a red precipitate formed 
and the reaction solution became faint red (almost colorless). The contents were cooled in 
an ice bath and the red solid collected by vacuum filtration and dried under vacuum for 15 
min to yield 3.02 g (59%) of dihydrazinyltetrazine as a red amorphous powder. The product 
was carried immediately to the next step. 
25 
 
 
Dichlorotetrazine (5). A 100 mL round bottom flask, was charged with dihydrazinylte-
trazine (2.95 g, 20.8 mmol) and suspended in acetonitrile (40 mL) then cooled in an ice 
bath. Trichloroisocynanuric acid (9.89 g, 42.6 mmol, 2.05 equiv) was dissolved in acetoni-
trile (30 mL) and added dropwise over 15 minutes. The ice bath was removed and the 
contents stirred at room temperature for 1.0 hour, the color of the solution changed from 
red to orange. The reaction was vacuum filtered, the white solid was rinsed with acetonitrile 
(2 × 5 mL) and the filtrate was collected and evaporated (70 torr, bath temperature 22oC) 
to give a red-orange solid. The crude material was dissolved in CH2Cl2 (15 mL) and filtered 
through a pad of celite (3.5 cm diameter × 8 cm length), the column was eluted with di-
chloromethane until the solution eluent ran colorless. The solvent was stripped under re-
duced pressure (100 torr, bath temperature 22oC) to yield 3.10 g (99%) of dichlorotetrazine 
as a waxy, orange solid. 13C NMR (126MHz, CDCl3) δ = 168.3.  
The material can be further purified by sublimation; heating the product in a subliminator 
at 70oC under a nitrogen atmosphere. 
 
 
 
 
26 
 
Procedures for Manual Solid-Phase Peptide Synthesis 
Resin Washing Procedures. Resin washing was conducted with the indicated solvent and 
was allowed to contact the resin for 30 seconds during each wash. The solvent was pushed 
through the frit using an “air push” apparatus made from a 15 mL disposable syringe and 
a 14/20 septum, or nitrogen gas was used in cases when an inert atmosphere is a require-
ment. 
General Procedures for the Resin Loading 
 
 
Wang Resin Amino Acid Loading.  Wang resin (0.22 mmol) was placed in a peptide 
synthesis vessel and the resin was swelled in CH2Cl2 (10 mL) for 1.0 hour. The solvent 
was drained and a pre-mixed solution consisting of Fmoc-AA-OH (0.88 mmol, 4 equiv), 
MSNT (0.88 mmol, 4 equiv) and methyl imidazole (0.66 mmol, 3 equiv) dissolved in 
CH2Cl2 (5 mL) was added to the resin. The contents were gently rocked for 2.0 hours, then 
drained and the resin washed with CH2Cl2 (3 × 5 mL). The procedure was repeated and the 
resin carried on to the next step. 
 
 
N-Methyl Indole AM Resin Amino Acid Loading.  N-Methyl indole resin (0.22 mmol) 
was placed in a peptide synthesis vessel and the resin was swelled in CH2Cl2 (10 mL) for 
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1.0 hour. The solvent was drained and the resin was washed with DMF (3 × 6 mL) then 
treated with 20% piperidine/DMF (2 × 6 mL) allowing the solution to contact the resin for 
10 minutes. The resin was washed with DMF (3 × 5 mL), then a pre-mixed solution con-
sisting of Fmoc-AA-OH (1.1 mmol, 5 equiv), HBTU (1.1 mmol, 5 equiv), oxyma (1.1 
mmol, 5 equiv) and DIPEA (2.2 mmol, 10 equiv) dissolved in DMF (5 mL) was added to 
the resin. The contents were rocked gently for 1.0 hour, then drained and the resin washed 
with DMF (3 × 5 mL). The coupling procedure was repeated and the resin carried on to the 
next step. 
 
 
2-Chlorotrityl Chloride Resin Amino Acid Loading. 2-Chlorotrityl chloride resin (0.40 
mmol) was placed in a peptide synthesis vessel and the resin was swelled in CH2Cl2 (10 
mL) for 1 h. The solvent was drained and the resin was then treated with a pre-mixed 
solution of Fmoc-AA-OH (0.48 mmol, 1.2 equiv), and DIPEA (1.6 mmol, 4 equiv) dis-
solved in CH2Cl2 (5 mL) was added to the resin. The contents were rocked gently for 1 h, 
then drained and the resin washed with DMF (3 × 5 mL). The coupling procedure was 
repeated and the resin carried on to the next step. 
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Rink Resin Amino Acid Loading. Rink Novagel resin (0.10 mmol) was placed in a pep-
tide synthesis vessel and the resin was swelled in CH2Cl2 (10 mL) for 1 h. The solvent was 
drained and the resin was washed with DMF (3 × 6 mL) then treated with 20% piperi-
dine/DMF (2 × 6 mL) allowing the solution to contact the resin for 10 minutes. The resin 
was washed with DMF (5 × 6 mL) and a pre-mixed solution of Fmoc-protected amino acid 
(0.50 mmol, 5 equiv), HBTU (190 mg, 0.5 mmol, 5 equiv), oxyma (71 mg, 0.5 mmol, 5 
equiv) and DIPEA (174 µL, 1.0 mmol, 10 equiv) dissolved in DMF (4 mL) was added to 
the resin. The contents were rocked gently for 1 h, then drained and the resin washed with 
DMF (3 × 6 mL).  
General Procedure for Manual Solid-Phase Peptide Synthesis 
 
Solid-Phase Peptide Synthesis (SPPS). The resin-bound Fmoc-amino acid (0.1 mmol) 
was washed with DMF (3 × 5 mL) and then treated with a solution of 20% piperidine/DMF 
(2 × 6 mL) allowing each treatment to contact the resin for 5 minutes. The resin was washed 
with DMF (5 × 6 mL), then a pre-mixed solution of Fmoc-protected amino acid (0.5 mmol, 
5.0 equiv), HBTU (190 mg, 0.5 mmol, 5.0 equiv), oxyma (71 mg, 0.5 mmol, 5.0 equiv) 
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and DIPEA (174 μL, 1.0 mmol, 10.0 equiv) dissolved in DMF (4 mL) was added to the 
resin. The contents were rocked gently for 1 h, then drained and the resin washed with 
DMF (3 × 5 mL). The Fmoc deprotection procedure was repeated followed by the coupling 
of the next amino acid in the sequence to synthesize the desired peptide.  
General Procedure for Peptide Cleavage and Global Deprotection 
 
Cleavage Cocktail A: TFA/EDT/TIPSH/water (92.5: 2.5: 2.5: 2.5) Peptides with Cys  
Cleavage Cocktail B: TFA/thioanisole/EDT/water (87.5: 5: 5: 2.5) Peptides with Cys & 
Trp, Arg 
Cleavage Cocktail C: TFA/thioanisole/EDT/TIPSH/water (87.5:5:2.5:2.5:2.5) Peptides 
with Cys & Met 
The resin-bound peptide (~0.1 mmol) was pre-swelled in CH2Cl2 for 30 minutes and then 
treated with cleavage cocktail A, B or C (7 mL) and stirred under a nitrogen atmosphere 
for 4 hours. The filtrate was collected and additional cleavage cocktail (3 ⨯ 1 mL) was 
used to wash the resin. The pooled filtrates were condensed (ca. 1 mL) and Et2O (15 mL) 
was added to precipitate the peptide. The white precipitate was collected by vacuum filtra-
tion and the solids wash with additional Et2O. The crude peptide was dried in vacuo over-
night and purified by reverse-phase high-pressure liquid chromatography (HPLC). 
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Preparation of 13C Enriched Cysteine Amino Acids for SPPS 
 
A 25 mL round bottom flask was charged with labeled L-cysteine-1-13C (0.52g, 4.3 mmol) 
and monomethoxytrityl chloride (1.98g, 6.4 mmol, 1.5 equiv) then suspended in DMF (6 
mL) and stirred for 72 hours. The product was precipitated out of solution by addition of 
aqueous NaOAc (1.2M, 25 mL) and the solid collected by vacuum filtration. The crude 
product was recrystallized from acetone (20 mL, heated to 50oC for 30 minutes) concen-
trated to half the volume and cooled in an ice bath to yield 1.36g (80%) of SI-1 as a white 
solid: 1H NMR (500 MHz, DMSO-d6) δ 7.34-7.19 (m, 12H), 6.89 (d, J = 9.0, Hz, 2H), 3.74 
(s, 3H), 2.98 (dt, J = 9.0, 4.5 Hz, 1H), 2.60 (ddd, J = 12.5, 4.0, 3.0 Hz, 1H), 2.43 (ddd, J = 
12.0, 9.0, 2.0 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 169.1, 158.3, 145.3, 136.7, 131.0, 
129.6, 128.6, 127.3, 113.9, 66.2, 55.8, 54.0 (d, J = 50 Hz), 34.2; HRMS (ES) m/z 417.1319 
[(M+Na)+; calcd for C22
13CH23NO3NaS: 417.1330]. 
 
The S-protected cysteine-1-13C (1.35g, 3.4 mmol) was transferred to a 100 mL round bot-
tom flask and dissolved in water (35 mL) and 1,4-dioxane (10 mL). The solution was 
cooled to 0oC and solid sodium carbonate (0.91g, 8.5 mmol, 2.5 equiv) was added followed 
by the dropwise addition of Fmoc-Cl dissolved in 1,4-dioxane (20 mL) over 5 minutes. 
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The reaction was stirred for 3 hours at 0oC and then 10 hours at ambient temperature. The 
solvent was concentrated and an aqueous solution of 5% KHSO4 was added until the mix-
ture reached pH 2. The contents were then extracted with EtOAc (4 × 25 mL) and the 
pooled organics were dried over Na2SO4, then stripped to give a brown oil which solidified 
into a white solid upon standing overnight. The crude material was purified by silica-gel 
chromatography using an isocratic 5% MeOH/CH2Cl2 eluent to yield 0.81g (77%) of SI-2 
as white foam: 1H NMR (500 MHz, CDCl3) δ 7.77 (t, J = 6.5, 2H), 7.61 (t, J = 6.5, 2H), 
7.42-7.40 (m, 6H), 7.32-7.26 (m, 8H), 7.22-7.19 (m, 2H), 6.80 (d, J = 9.0 Hz, 2H), 5.20 (d, 
J = 8.0 Hz, 1H), 4.45-4.37 (m, 2H), 4.33-4.28 (m, 1H), 4.24 (t, J = 7.0 Hz, 1H), 3.76 (s, 
3H), 2.75 (bs, 2H); 13C NMR (125 MHz, CDCl3) δ 174.9, 158.4, 156.0, 144.6, 141.4, 136.4, 
130.9, 129.5, 128.2, 127.9, 127.3, 127.0, 125.2, 120.1, 113.5, 67.4, 67.0, 55.4, 53.0 (d, J = 
58 Hz), 47.2, 33.7; HRMS (ES) m/z 639.2003 [(M+Na)+; calcd for C37
13CH33NO5NaS: 
639.2001]. 
 
SI-3: Fmoc-Cysteine(St-Bu)-OH (1-13C). A 50 mL round bottom flask was charged with 
Fmoc-Cysteine(Mmt)-OH (1-13C) (0.60g, 0.98 mmol) in 95:5:3 CH2Cl2/TFA/TES solution 
(20 mL). The mixture was stirred at room temperature for 1h under a nitrogen atmosphere. 
The solvent was evaporated under reduced pressure, and the crude residue was washed 
three times with toluene and after each washing it was evaporated to dryness. The solid 
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residue was transferred to a sintered funnel and washed twice with pentane. The remaining 
residue was transferred to a microwave vial (2-5 mL) then dissolved in 2.5 mL of buffer 
containing 10 mM NH4OAc in acetonitrile/water (3:2). 2-Methyl-2-propanethiol (1.1 mL, 
9.8 mmol) and 0.75 mL DMSO were added, and the reaction mixture was irradiated for 5 
min at 150oC. After TLC had indicated complete consumption of the starting material, the 
reaction mixture was concentrated and extracted with brine and CH2Cl2. The organic layer 
was dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was puri-
fied by silca-gel chromatography using an isocratic 3% MeOH/CH2Cl2 eluent to yield 0.38 
g (91%) of SI-3 as white foam: 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 8.0 Hz, 2H), 
7.62 (d, J = 7.5 Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 5.71 (d, J = 7.5 
Hz, 1H), 4.73-4.68 (m, 1H), 4.44-4.36 (m, 2H), 4.26 (t, J = 7.5 Hz, 1H), 3.28 (dt, J = 13.5, 
4.5 Hz, 1H), 3.19 (dd, J = 13.5, 5.5 Hz, 1H), 1.33 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 
175.0, 156.0, 143.8, 141.3, 127.8, 127.2, 125.3, 120.1, 67.5, 53.8 (d, J = 60 Hz), 48.4, 47.1, 
42.1, 29.9; HRMS (ES) m/z 433.1347 [(M+H)+; calcd for C21
13CH26NO4S2: 433.1337]. 
General Procedures for the Preparation of 18O Enriched Amino Acids 
The 18O enrichment of 13C enriched Fmoc-Ala-OH and Fmoc-Cys(St-Bu) A 25 mL tear 
drop flask equipped with a stirring bar was charged with ~ 500 mg of 13C isotopically 
enriched amino acid. The amino acid was dissolved in 3 mL of a hot 1:1 dioxane and 97% 
18O enriched water which was 0.25M in HCl. The solution was stirred under reflux and 
under nitrogen for 12 h before it was concentrated in vacuo. LC-MS analysis was con-
ducted to determine the isotopic enrichment of the amino acid residues and the procedure 
was repeated if necessary to obtain an 18O enrichment level of 95% or higher. 
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General Procedure for Introduction of Dichlorotetrazine to Resin-Bound Peptide 
 
The resin-bound peptide (0.22 mmol) was swelled in CH2Cl2 (10 mL) for 1.0 hour. The 
peptide synthesis vessel was set-up under an inert atmosphere by connecting it to a two-
neck round bottom flask fitted with a septum, such that the resin was kept under a blanket 
of nitrogen and could also be bubbled through the bottom of the frit to agitate the resin. 
The solvent was drained and a pre-mixed solution of CH2Cl2/TIPSH/TFA [(92.5:5.0:2.5 
for loaded Wang resin, 6 mL)/ (95:4:1 for loaded N-methyl indole AM resin, 6 mL)] was 
added to the resin and the orange solution agitated for 3 minutes, the contents were drained 
and the resin washed with CH2Cl2 (10 mL). The procedure was repeated 4 additional times 
until the reaction solution went clear suggesting the monomethoxytrityl groups had been 
completely removed. The resin was washed with 10% DIPEA/ClCH2CH2Cl (3 × 5 mL). 
To the resin was added a solution of dichlorotetrazine (0.24 mmol, 1.1 equiv) in 
ClCH2CH2Cl (5 mL) followed by the addition of DIPEA (0.5 mL) neat. The peptide vessel 
was wrapped in foil to exclude ambient light and the contents were gently rocked for 18 
hours. The filtrate was drained and the resin washed with CH2Cl2 (3 × 5 mL), MeOH (3 × 
5 mL) and CH2Cl2 (3 × 5 mL). 
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Modified S,S-Tetrazine Tethering Protocol for Synthesis of 22. The resin-bound pep-
tide 6 (0.22 mmol) was swelled in CH2Cl2 (10 mL) for 1.0 hour. The peptide synthesis 
vessel was set-up under an inert atmosphere such that the resin was kept under a blanket 
of nitrogen and could also be bubbled through the bottom of the frit to agitate the resin. 
The solvent was drained and a pre-mixed solution of tributylphosphine (2.23 g, 11.0 mmol) 
in NMP/H2O (9:1, 6 mL) was added to the resin and the solution agitated for 1 h, the con-
tents were drained and the resin washed with CH2Cl2 (10 mL) and the procedure was re-
peated one additional time. Afterwards, a pre-mixed solution of CH2Cl2/TIPSH/TFA 
(92.5:5.0:2.5, 6 mL) was added to the resin and the orange solution agitated for 3 minutes, 
the contents were drained and the resin washed with CH2Cl2 (10 mL). The procedure was 
repeated 4 additional times until the reaction solution went clear suggesting the monometh-
oxytrityl groups had been completely removed. The resin was washed with 10% DI-
PEA/ClCH2CH2Cl (3 × 5 mL). To the resin was added a solution of dichlorotetrazine (0.24 
mmol, 1.1 equiv) in ClCH2CH2Cl (5 mL) followed by the addition of DIPEA (0.5 mL) 
neat. The peptide vessel was wrapped in foil to exclude ambient light and the contents were 
gently rocked for 18 hours. The filtrate was drained and the resin washed with CH2Cl2 (3 
× 5 mL), MeOH (3 × 5 mL) and CH2Cl2 (3 × 5 mL). 
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Compound 11 was purified by reverse-phase chromatography (gradient 5 – 30% organic 
over 10 minutes) to give 24.6 mg (30.0%) of 11 as an orange amorphous powder after 
lyophilization. HRMS (ES) m/z 374.0699 [(M+H)+; calcd for C11H16N7O4S2: 374.0705]; 
IR (ATR) 1644 (s), 1531 (m), 1410 (m), 1245 (s), 1202 (m), 1144 (m); 1H NMR (500 MHz, 
DMSO-d6) δ 8.78 (d, J = 8.5 Hz, 1H), 8.66 (d, J = 6.5 Hz, 1H), 8.26 (brs, 3H), 4.80 (ddd, 
J = 6.5, 4.5, 2.0 Hz, 1H), 4.73 (dd, J = 16.0, 3.0 Hz, 1H), 4.54 (dd, J = 15.0, 4.5 Hz, 1H), 
4.32 (t, J = 3.0 Hz, 1H), 4.21 (dq, J = 8.5, 7.0 Hz, 1H), 3.55 (dd, J = 15.0, 2.0 Hz, 1H), 
3.50 (dd, J = 16.0, 3.0 Hz, 1H), 1.03 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) 
δ 171.2, 170.8, 170.7, 169.5, 164.7, 51.7, 51.1, 47.6, 30.4, 30.0, 19.7. 
 
Compound 12 was purified by reverse-phase chromatography (gradient 10 – 80% organic 
over 12 minutes) to give 14.7 mg (15.6%) of 12 as an orange amorphous powder after 
lyophilization. HRMS (ES) m/z 429.1145 [(M+H)+; calcd for C14H21N8O4S2: 429.1127]; 
IR (ATR) 1647 (m), 1542 (w), 1410 (w), 1377 (w), 1067 (s); 1H NMR (500 MHz, DMSO-
d6) δ 8.50 (d, J = 7.5 Hz, 1H), 8.47 (d, J = 9.0 Hz, 1H), 8.03 (d, J = 7.5 Hz, 1H), 7.99 (q, J 
= 4.5 Hz, 1H), 4.77 (dt, J = 7.0, 3.5 Hz, 1H), 4.66 (ddd, J = 6.5, 4.5, 2.0 Hz, 1H), 4.48 (dd, 
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J = 15.0, 4.5 Hz, 1H), 4.41 (dd, J = 15.0, 2.5 Hz, 1H), 4.16 (dq, J = 8.5, 7.0 Hz, 1H), 3.44 
(overlapping dd, J = 14.5, 2.0 Hz, 1H), 3.32 (dd, J = 15.0, 3.5 Hz, 1H), 2.63 (d, J = 4.5 Hz, 
3H), 1.89 (s, 3H), 1.03 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 171.6, 171.0, 
170.5, 169.2, 168.9, 167.3, 51.4, 50.9, 47.4, 32.9, 30.2, 26.0, 22.5, 19.8. 
 
 Compound 14 was purified by reverse-phase chromatography (gradient 5 – 30% organic 
over 9 minutes) to give 16.2 mg (18.4%) of 14 as an orange amorphous powder after ly-
ophilization: HRMS (ES) m/z 402.1011 [(M+H)+; calcd for C13H20N7O4S2: 402.1018];
 IR 
(ATR) 3292 (w, br), 2974 (w), 1644 (s), 1537 (m), 1411 (m), 1391 (m), 1242 (m), 1203 
(w), 1144 (w), 1052 (w), 893 (w) cm-1; 1H NMR (500 MHz, D2O) δ 4.69 (dd, J = 15.1, 4.7 
Hz, 1H), 4.53 (dd, J = 4.0, 2.6 Hz, 1H), 3.87 (d, J = 8.8 Hz, 1H), 3.61 (dd, J = 16.3, 4.3 
Hz, 1H), 3.60 (dd, J = 14.9, 2.2 Hz, 1H), 1.86-1.79 (m, 1H), 0.82 (d, J = 6.6 Hz, 6H); 13C 
NMR (125 MHz, D2O) δ 174.2, 172.3, 171.6, 169.3, 166.4, 59.1, 51.2, 31.7, 30.8, 30.6, 
18.1, 18.0. 
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Compound 15 was purified by reverse-phase chromatography (gradient 5 – 30% organic 
over 9 minutes) to give 14.5 mg (16.9%) of 15 as an orange amorphous powder after ly-
ophilization: HRMS (ES) m/z 390.0656 [(M+H)+; calcd for C11H16N7O5S2: 390.0654]; IR 
(ATR) 3309 (m, br), 1651 (s), 1646 (s), 1635 (s), 1558 (s), 1540 (s), 1418 (m), 1249 (s), 
1202 (w), 1138 (w), 1058 (w), 894 (w) cm-1; 1H NMR (500 MHz, D2O) δ  4.66 (overlapping 
dd, J = 14.9, 4.5 Hz, 1H), 4.65 (overlapping m, 1H), 4.54 (t, J = 3.1 Hz, 1H), 4.30 (t, J = 
6.6 Hz, 1H), 3.68 (dd, J = 11.5, 6.2 Hz, 1H), 3.61 (dd, J = 16.2, 3.8 Hz, 1H), 3.58 (d, J = 
11.6, 1H), 3.56 (dd, J = 11.6, 7.0 Hz, 1H); 13C NMR (125 MHz, D2O) δ 174.39, 172.43, 
169.57, 169.35, 166.56, 61.79, 54.59, 53.91, 51.45, 30.90, 30.04. 
 
Compound 16 was purified by reverse-phase chromatography (gradient 5 – 30% organic 
over 9 minutes) to give 14.4 mg (15.7%) of 16 as an orange amorphous powder after ly-
ophilization: HRMS (ES) m/z 431.1306 [(M+H)+; calcd for C14H23N8O4S2: 431.1284]; IR 
(ATR) 3262 (w, br) 3083 (w, br), 1670 (s), 1642 (s), 1540 (m), 1418 (w),  1395 (w), 1245 
(m), 1197 (s), 1138 (s), 894 (w) cm-1; 1H NMR (500 MHz, D2O) δ 4.87 (d, J = 4.0, 1.5 Hz, 
1H), 4.76 (overlapping, 1H), 4.68 (dd, J = 15.2, 4.8, 1H), 4.50 (t, J = 3.2 Hz, 1H), 4.16 (t, 
J = 7.5 Hz, 1H), 3.63 (dd, J = 15.1, 1.6 Hz, 1H), 3.61 (dd, J = 16.2, 4.0 Hz, 1H), 2.91 (t, J 
= 7.5 Hz, 2H), 1.71-1.58 (m, 2H), 1.54-1.36 (m, 2H), 1.28-1.18 (m, 2H); 13C NMR (125 
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MHz, D2O) δ 173.1, 172.3, 171.8, 169.7, 166.2, 53.0, 52.7, 51.4, 39.2, 32.4, 30.5, 30.4, 
26.3, 21.8. 
 
Compound 17 was purified by reverse-phase chromatography (gradient 5 – 30% organic 
over 9 minutes) to give 14.4 mg (15.7%) of 17 as an orange amorphous powder after ly-
ophilization: HRMS (ES) m/z 418.0602 [(M+H)+; calcd for C12H16N7O6S2: 418.0604]; IR 
(ATR) 3300 (w, br), 1654 (s), 1556 (m), 1541 (m), 1404 (m), 1242 (s), 1200 (m), 1143 
(w), 1053 (w), 894 (w) cm-1; 1H NMR (500 MHz, D2O) δ 4.74 (dd, J = 15.9, 2.4 Hz, 1H), 
4.68 (dd, J = 14.7, 4.3 Hz, 1H), 4.65 (dd, J = 4.3, 1.2 Hz, 1H) 4.60 (dd, J = 9.0, 5.3 Hz, 
1H), 4.46 (dd, J = 3.8, 2.7 Hz, 1H), 3.59 (dd, J = 16.2, 4.2 Hz, 1H), 3.57 (dd, J = 14.6, 1.4 
Hz, 1H), 2.74 (dd, J = 16.0, 5.4 Hz, 1H), 2.59 (dd, J = 16.0, 9.1 Hz, 1H); 13C NMR (125 
MHz, D2O) δ 175.83, 175.55, 173.88, 172.09, 170.91, 167.80, 55.65, 52.61, 51.55, 39.43, 
32.22, 31.74. 
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Compound 18 was purified by reverse-phase chromatography (gradient 5 – 30% organic 
over 9 minutes) to give 21.4 mg (24.3%) of 18 as an orange amorphous powder after ly-
ophilization: HRMS (ES) m/z 400.0857 [(M+H)+; calcd for C13H18N7O4S2: 400.0862]; IR 
(ATR) 1652 (s), 1506 (m), 1241 (s), 1195 (m), 1134 (m), 1055 (w), 896 (w) cm-1; 1H NMR 
(500 MHz, D2O) δ 4.67 (dd, J = 4.0, 2.5 Hz, 1H), 4.48 (d, J = 16.0 Hz,  1H), 4.40 (br t, J 
=5.0, 1H), 3.79 (dd, J = 10.0, 3.0 Hz, 1H), 3.77 (dd, J = 9.0, 2.5 Hz, 1H) 3.68 (m, 2H), 3.62 
(dd, J = 15.5, 5.5 Hz, 1 H), 3.59 (dd, J = 15.2, 2.2 Hz, 1H), 2.41-2.31 (m, 1H), 2.11-2.04 
(m, 1H), 1.96-1.91 (m, 2H); 13C NMR (125 MHz, D2O) δ 175.0, 174.7, 173.5, 171.0, 168.4, 
61.5, 56.0, 49.4, 49.3, 32.0, 31.2, 30.5, 25.7. 
 
Compound 19 was purified by reverse-phase chromatography (gradient 5 – 30% organic 
over 9 minutes) to give 7.5 mg (7.0%) of 19 as an orange amorphous powder after lyoph-
ilization: HRMS (ES) m/z 489.1133 [(M+H)+; calcd for C19H21N8O4S2: 489.1127]; IR 
(ATR) 3302 (w, br), 1641 (s), 1541 (m), 1529 (m), 1457 (w), 1416 (m), 1242 (s), 1200 
(w), 1055 (w), 896 (w) cm-1; 1H NMR (500 MHz, D2O/CD3OD) δ 7.53 (d, J = 7.8 Hz, 
1H), 7.34 (d, J = 8.2 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 5.35 (s, 
1H), 4.72 (dd, J = 14.8, 4.4 Hz, 1H), 4.37 (t, J = 7.6 Hz, 1H), 4.35 (t, J = 3.2 Hz, 1H), 
40 
 
4.20 (dd, J = 4.0, 2.5 Hz , 1H), 3.54 (dd, J = 16.0, 4.1 Hz, 1H), 3.48 (dd, J = 14.8, 2.0 Hz, 
1H), 3.12 (dd, J = 13.9, 8.1 Hz, 1H), 3.01 (dd, J = 14.2, 6.8 Hz, 1H). 
 
Compound 20 was purified by reverse-phase chromatography (gradient 5 – 30% organic 
over 9 minutes) to give 6.5 mg (8.0%) of 20 as an orange amorphous powder after lyophi-
lization: HRMS (ES) m/z 360.0352 [(M+H)+; calcd for C10H14N7O4S2: 360.0549];
 IR 
(ATR) 3055 (m, br), 1651 (s), 1538 (m), 1413 (m), 1396 (m), 1238 (s), 1199 (s), 1139 (s), 
958 (m), 892 (m) cm-1; 1H NMR (500 MHz, D2O) δ 4.72 (dd, J = 16.4, 2.3 Hz, 1H), 4.66 
(dd, J = 15.2, 4.6 Hz, 1H), 4.51 (app t, J = 3.3 Hz, 2H), 4.03 (d, J = 15.6 Hz, 1H), 3.63 (d, 
J = 16.3 Hz, 1H), 3.62 (d, J = 16.3 Hz, 1H), 3.45 (d, J = 15.6 Hz, 1H); 13C NMR (125 
MHz, D2O) δ 173.3, 172.2, 169.7, 169.1, 166.7, 53.2, 51.1, 42.2, 30.5, 30.3. 
 
Compound 21 was purified by reverse-phase chromatography (gradient 5 – 30% organic 
over 10 minutes) to give 21.5 mg (26%) of 21 as an orange amorphous powder after ly-
ophilization: HRMS (ES) m/z 377.0786 [(M+H)+; calcd for C10
13CH16N7O3
18OS2: 
377.0781]; IR (ATR) 1676 (s), 1594 (s), 1546 (w), 1530 (w), 1416 (w), 1244 (m), 1202 
41 
 
(s), 1138 (s); 1H NMR (500 MHz, DMSO-d6) δ 8.77 (d, J = 8.5 Hz, 1H), 8.65 (dd, J = 6.5, 
3.5 Hz, 1H), 8.33 (d, J = 5.0 Hz, 1H), 8.28 (d, J = 5.0 Hz, 1H), 4.84-4.81 (m, 1H), 4.74 
(dd, J = 15.5, 3.0 Hz, 1H), 4.55 (dd, J = 14.5, 4.5 Hz, 1H), 4.35-4.31 (m, 1H), 4.24-4.18 
(m, 1H), 3.54 (brd, J = 14.5 Hz, 1H), 3.50 (dd, J = 16.0, 3.0 Hz, 1H), 1.03 (dd, J = 7.0, 4.0 
Hz, 3H); 1H NMR (500 MHz, D2O) δ 4.83 (dq, J = 5.0, 2.5 Hz, 1H), 4.75 (J = 15.5, 3.0 
Hz, 1H), 4.68 (dd, J = 15.0, 4.5 Hz, 1H), 4.48 (dd, J = 3.5, 3.0 Hz, 1H), 4.22 (dq, J = 7.0, 
4.0 Hz, 1H), 3.62 (dd, J = 15.0, 2.0 Hz, 1H), 3.61 (dd, J = 15.0, 4.0 Hz, 1H), 1.23 (dd, J = 
7.0, 4.0 Hz, 3H); 13C NMR (125 MHz, D2O) δ 172.7 172.2, 171.7, 169.1, 165.3, 52.5, 50.9, 
48.2 (d, J = 54 Hz), 30.0, 29.7, 17.8. 
 
Compound 22 was purified by reverse-phase chromatography (gradient 5 – 30% organic 
over 10 minutes) to give 26.7 mg (32%) of 22 as an orange amorphous powder after ly-
ophilization: HRMS (ES) m/z 380.0843 [(M+H)+; calcd for C9
13C2H16N7O2
18O2S2: 
380.0857]; IR (ATR) 1677 (m), 1574 (s), 1413 (m), 1242 (s), 1202 (m), 1144 (m), 1055 
(w); 1H NMR (500 MHz, DMSO-d6) δ 8.76-8.69 (m, 1H), 8.57-8.52 (m, 1H), 4.78-4.74 
(m, 1H), 4.72 (brd, J = 15.5 Hz, 1H), 4.56 (dd, J = 15.0, 4.0 Hz, 1H), 4.33-4.29 (m, 1H), 
4.27-4.20 (m, 1H), 3.54 (brd, J = 15.0 Hz, 1H), 3.54-3.50 (m, 1H), 1.05 (dd, J = 7.0, 4.0 
Hz, 3H); 1H NMR (500 MHz, 1:9 D2O/H2O) δ 8.75 (dd, J = 8.5, 3.5 Hz, 1H), 8.27 (t, J = 
5.0 Hz, 1H), 4.59-4.55 (m, 1H), 4.38 (q, J = 3.5 Hz, 1H), 4.16-4.09 (m, 1H), 3.53-3.47 (m, 
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1H), 1.13 (dd, J = 7.0, 4.5 Hz, 3H); 13C NMR (125 MHz, 1:9 D2O/H2O) δ 177.2, 174.1, 
172.7 (d, J = 2 Hz), 170.2, 165.9 (d, J = 2 Hz), 53.7, 51.5 (d, J = 54 Hz), 48.9 (d, J = 54 
Hz), 30.8, 30.3, 18.3.  
 
Compound 13. A solution of tetrazine peptide 12 (2.0 mg) was dissolved in CD3OD (500 
μL) and transferred to an NMR tube. The contents were suspended in a Rayonet photore-
actor at a distance of about 5 cm from eight Hitachi FL8BL-8 UV-A (λMax = 365 nm) lamps. 
The solution was irradiated for 4 hours and the solution became colorless, an indication 
that the sample had reached complete conversion. Analysis by H-NMR showed quantita-
tive conversion to furnish 13: HRMS (ES) m/z 423.0870 [(M+Na)+; calcd for 
C14H20N6O4NaS2: 423.0885];
 1H NMR (500 MHz, DMSO-d6) δ 8.48 (d, J = 7.0 Hz, 1H), 
8.41 (d, J = 8.0 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.01 (q, J = 4.5 Hz, 1H), 4.64 (dt, J = 
8.0, 4.5 Hz, 1H), 4.49 (dt, J = 7.5, 5.5 Hz, 1H), 4.24 (pent, J = 7.0 Hz, 1H), 3.41 (dd, J = 
13.5, 5.5 Hz, 1H), 3.24 (dd, J = 13.5, 7.5 Hz, 1H), 3.18 (dd, J = 13.5, 8.5 Hz, 1H), 2.61 (d, 
J = 4.5 Hz, 3H), 1.90 (s, 3H), 1.25 (d, J = 7.0 Hz, 3H); 13C NMR (500 MHz, DMSO-d6) δ 
172.4, 170.2, 169.1, 168.8, 113.3, 113.2, 52.6, 52.3, 49.2, 35.5, 35.3, 26.0, 22.7, 17.6.  
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Compound 23. A 10 mL tear drop flask equipped with a stir bar was charged with a solu-
tion of 7 (15.0 mg, 0.035 mmol) in methanol (5 mL). A spatula tip of 10% palladium on 
carbon (50% wet with water) was added to the solution. The heterogeneous mixture was 
flushed with hydrogen gas using a balloon and then stirred under a hydrogen gas environ-
ment for 5 min. The mixture was then filtered through a pad of silica gel and the filtrate 
concentrated in vacuo to afford, without any required purification, 14.9 mg (98%) of 23 as 
a colorless oil: HRMS (ES) m/z 435.1129 [(M+H)+; calcd for C14H23N6O6S2: 435.1121]; 
IR (CH2Cl2) 3047 (s), 2985 (s), 2306 (m), 1745 (s), 1679 (s), 1623 (m), 1510 (s); 
1H NMR 
(500 MHz, CD3OD) δ 4.69 (dd, J = 8.0, 4.5 Hz, 1H), 3.73 (s, 3H), 3.46 (dd, J = 14.0, 4.5 
Hz, 1H), 3.22 (dd, J = 14.0, 8.0 Hz, 1H), 1.99 (s, 3H); 1H NMR (500 MHz, DMSO-d6) δ 
8.89 (s, 1H), 4.43 (d, J = 7.5 Hz, 1H), 4.89 (ddd, J = 9.0, 7.5, 5.0 Hz, 1H), 3.63 (s, 3H), 
3.33 (dd, J = 13.5, 5.0 Hz, 1H), 3.06 (dd, J = 13.5, 9.0 Hz, 1H), 1.86 (s, 3H); 13C NMR 
(125 MHz, CD3OD) δ 173.5,  172.3, 151.8, 54.0, 53.2, 33.2, 22.5; 13C NMR (125 MHz, 
DMSO-d6) δ 170.7,  169.3, 149.4, 52.1, 51.5, 31.2, 22.2.  
Compound 7 (from oxidation of 23). To a 10 mL tear drop flask charged with 23 (5.2 mg, 
0.012 mmol) was added methanol (5 mL). The solution was allowed to stand exposed to 
air for 8 h after which the solution, which turned from colorless to orange, was concentrated 
in vacuo and then chromatographed on silica gel using 5% methanol/ethyl acetate as the 
eluent to give 5.0 mg (97%) of 7 as an orange oil: 1H NMR (500 MHz, CD3OD) δ 4.89 
(dd, J = 8.5, 5.0 Hz, 1H), 4.00 (dd, J = 14.0, 5.0 Hz, 1H), 3.77 (s, 3H), 3.50 (dd, J = 14.0, 
8.5 Hz, 1H), 1.97 (s, 3H); 13C NMR (125 MHz, CD3OD) δ 173.7,  173.6, 172.1, 53.3, 52.8, 
32.7, 22.4. 
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Compound 24. Prepared by the general SPPS protocol, initially from 0.11 mmol loaded 
Wang resin and was purified by reverse-phase chromatography (gradient 10 – 80% organic 
over 10 min) to give 11.9 mg (16%) of 24 as an orange amorphous powder after lyophi-
lization: HRMS (ES) m/z 700.1962 [(M+Na)+; calcd for C27H35N9O8NaS2: 700.1948].  
 
Compound 25. To a 10 mL tear-drop flask charged with 24 (2.0 mg, 0.0030 mmol) was 
added a solution of TFA (3mL). After stirring for 24 h, completion of the reaction was 
observed by LC-MS and the solution was concentrated under reduced pressure. The result-
ing residue was taken into water (1 mL) and then purified by reverse-phase chromatog-
raphy (gradient 5% – 45% organic over 10 min) to give 1.5 mg (90%) of 25 as an orange 
amorphous powder after lyophilization: HRMS (ES) m/z 544.1777 [(M+H)+; calcd for 
C19H30N9O6S2: 544.1760]; 
1H NMR (500 MHz, DMSO-d6) δ 8.54 (d, J = 6.9 Hz, 1H), 8.48 
(d, J = 8.5 Hz, 1H), 8.18 (d, J = 7.9 Hz, 1H), 7.83 (d, J = 6.7 Hz, 1H), 7.74 (s, 4H), 4.74 
(ddd, J = 6.6, 4.9, 3.2 Hz, 2H), 4.54 (ddd, J = 14.3, 10.0, 3.7 Hz, 2H), 4.26 (td, J = 8.5, 4.9 
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Hz, 1H), 4.22 – 4.12 (m, 1H), 3.52 (dd, J = 14.8, 2.1 Hz, 1H), 3.37 (dd, J = 15.2, 3.5 Hz, 
1H), 1.88 (s, 3H), 1.52 (dt, J = 9.5, 4.7 Hz, 2H), 1.33 (q, J = 7.7 Hz, 2H), 1.24 (s, 2H), 1.00 
(d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 171.3, 171.1, 170.8, 170.7, 170.5, 
169.4, 166.8, 52.4, 51.6, 50.9, 47.4, 32.3, 30.9, 30.3, 26.5, 22.4, 22.3, 19.7. 
 
 
Compound 26. A 25 mL round bottom flask was charged with 11 (27.0 mg, 0.072 mmol) 
and NaHCO3 (15.1 mg, 0.180 mmol, 2.5 equiv) then dissolved in water (2.0 mL). A pre-
mixed solution of Boc-anhydride (23.7 mg, 0.109 mmol, 1.5 equiv) dissolved in 1,4-diox-
ane (2.0 mL) was added dropwise over 15 minutes (slow addition of Boc2O was found to 
give  better yields than adding in one portion) with stirring. After 2.0 hours, completion of 
the reaction was observed by LC-MS and the reaction solution was purified by reverse-
phase chromatography (gradient 10 – 80% organic over 10 minutes) to give 33.1 mg 
(97.0%) of 26 as an orange amorphous powder after lyophilization. HRMS (ES) m/z 
474.1232 [(M+H)+; calcd for C16H24N7O6S2: 474.1230]; IR (ATR) 3310 (w), 1720 (m), 
1666 (s), 1645 (s), 1535 (m), 1508 (m), 1238 (s), 1207 (m), 1166 (s), 1054 (w), 894 (m); 
1H NMR (500 MHz, DMSO-d6) δ 8.41 (d, J = 8.0 Hz, 1H), 8.23 (bs,  1H), 6.38 (d, J = 6.5 
Hz, 1H), 4.55-4.49 (m, 4H), 4.15 (pent, J = 7.0 Hz, 1H), 3.54 (dd, J = 15.5, 3.0 Hz, 1H), 
3.35 (overlapping d, J = 15.0, 1H), 1.39 (s, 9H), 1.01 (d, J = 7.0 Hz, 3H); 13C NMR (125 
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MHz, DMSO-d6) δ 171.1, 170.6, 170.4, 167.2, 163.19, 154.31, 78.6, 52.3, 51.9, 47.5, 32.7, 
30.9, 28.1, 19.7. 
 
Compound 27. Prepared by SPPS, initially from 0.25 mmol loaded methyl indole AM 
resin and purified by reverse-phase chromatography (gradient 5 – 60% organic over 10 
min) to give 116.1 mg (37%) of  27 as a white amorphous powder after lyophilization: 
HRMS (ES) m/z 1252.6707 [(M+H)+; calcd for C58H90N15O16: 1252.6690]; MALDI-TOF 
m/z 1274.399 [(M+Na)+; calcd for C58H89N15O16Na: 1274.6510].  
 
Compound 28. Prepared by SPPS, initially from 0.25 mmol loaded 2-chlorotrityl chloride 
resin and purified by reverse-phase chromatography (gradient 10 – 70% organic over 10 
min) to give 109.1 mg (38%) of 28 as a white amorphous powder after lyophilization: 
HRMS (ES) m/z 1160.5630 [(M+H)+; calcd for C56H78N11O16: 1160.5628]; MALDI-TOF 
m/z 1182.469 [(M+Na)+; calcd for C56H77N11O16Na: 1182.5448]. 
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Compound 10. To a 10 mL tear-drop flask containing Peptide  (30.8 mg, 0.019 mmol) in 
DMF (2.5 mL) was added dropwise a pre-mixed solution of I-36 (22.3 mg, 0.019 mmol, 
1.0 equiv), Oxyma (3.0 mg, 0.021 mmol, 1.1 equiv), HBTU (8.0 mg, 0.021 mmol, 1.1 
equiv) and DIPEA (8.4 µL, 0.048 mmol, 2.5 equiv) in DMF (1.5 mL). After stirring for 8 
h, the reaction solution was concentrated under reduced pressure. To the resulting residue 
was added neat TFA (4 mL). After stirring for 24 h, the solution was concentrated under 
reduced pressure, taken into acetonitrile/water (1:1), and then purified by reverse-phase 
chromatography (gradient 5 – 35% organic over 10 min) to give 10.5 mg (25%) of I-4 as 
an amorphous powder after lyophilization: HRMS (ES) m/z 2213.1260 [(M+H)+; calcd for 
C93H154N33O26S2: 2213.1184]; MALDI-TOF m/z 2213.598 [(M+H)
+; calcd for 
C93H154N33O26S2: 2213.1184]. 
 
Compound 9. Prepared by SPPS, initially from 0.050 mmol loaded methyl indole AM 
resin and purified by reverse-phase chromatography (gradient 5 – 35% organic over 10 
min) to give 13.7 mg (13%) of 9 as a white amorphous powder after lyophilization: HRMS 
(ES) m/z 2093.1575 [(M+Na)+; calcd for C91H155N29O26Na: 2093.1596]; MALDI-TOF m/z 
2071.014 [(M+H)+; calcd for C92H156N29O26: 2071.1776]. 
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CHAPTER 2. Stapling and Unstapling Peptides/Proteins with s-Te-
trazine 
 
Introduction 
Modulation of peptide and protein conformation comprises one of the principal deter-
minates of biofunction and molecular recognition.1 Throughout the late 1970s and 1980s, 
pioneers in the field such as Hirschmann2-3 , Hruby4-5 , and Kessler6-7 used conformational 
constraints within natural peptide hormones to lock the active conformations of these struc-
tures resulting in improved bioactivity and bioavailability compared to the natural prod-
ucts. These studies demonstrated the active conformation was much more than the simple 
two-dimensional linear sequence of amino acids, and began to establish the relationship 
between the overall three-dimensional peptide structure and function. Towards this end, 
macrocyclization has become an effective tactic to increase proteolytic stability, vary po-
larity and improve the overall drugability of peptides.8-10 
Inevitably the rational design of bioactive peptides now seeks to recapitulate the three-
dimensional structures that naturally occur in proteins such as, turns, β-sheets and helices 
(Figure 2.1). The ability to predict and prepare these structures holds the promise 
 
 
Figure 2.1. Design of Peptides to Mimic Bioactive Structures 
 
Turns β-Sheets Helices
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toward the development of the next generation of peptide based therapeutics. In moving 
forward, we will evaluate some of the methods used to restrict peptide conformation.  
Disulfide Bonds: Covalent Conformational Restraints Used in Nature 
 
One of the most prevalent covalent modification of peptides and proteins is the disulfide 
bond, second only to the peptide bond itself.  Indeed, nature uses this linkage to induce 
conformational restrictions for peptides/proteins to stabilize the overall three-dimensional 
structure.11 The secondary structure of proteins is important, not only for biofunction and 
molecular recognition, but also for reducing the exposure of vulnerable residues to prote-
ases. Peptides however are highly susceptible to proteolytic degradation; therein lies one 
of the main disadvantages of peptides as therapeutics. However, bioactive natural product 
peptides, such as the antimicrobial defensin peptides, the cysteine knot peptides, and small 
venom-derived peptides like the conotoxins, have all evolved with multiple disulfide bonds 
presumably to restrict the conformation and circumvent problems associated degradation. 
Nature’s valuable lesson of constraining the structure of a peptide sequence with disulfides, 
in turn, renders a more compacted and rigid framework that reduces the exposure of the 
peptide sequence toward proteolytic degradation.  
Peptide Stapling: Synthetic Macrocyclization Constraints 
 
Synthetic macrocyclization strategies have been developed to generate constrained pep-
tides with enhanced stability by tethering two side-chains within the peptide. The macro-
cyclization strategies that are used to induce and to stabilize the secondary structure of a 
peptide conformation comprises a tactic known as “stapling”. Although stapling protocols 
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have been developed for constructing β-sheets and turns,12 much more attention has been 
focused on stapling α-helices given that α-helices are the largest class of protein secondary 
structures and in turn have a major role in protein-protein interactions. Early synthetic ex-
amples of stapling tactics used to mimic α-helices were designed and prepared by inserting 
either a lactam or disulfide bridge. For example, studies at Hoffmann-La Roche on human 
growth hormone-releasing factor (GFP), linked the side-chains of the aspartic acid 8 and 
lysine 12 residues and found the peptide demonstrated improved potency and significant 
helical character in an aqueous solution.13 Later, Taylor and co-workers, applied this tactic 
for the construction of short peptide sequences, linking the side chains of glutamic acid and 
lysine i, i + 4 residues to form a lactam (Figure 2.2).14-15 This technique demonstrated that 
short sequences of amino acids retained helical conformation, however the 
 
 
Figure 2.2. Early Peptide Stapling Tactics 
 
lactam bridge proved highly sensitive to the position within the peptide. For example, when 
the placement of lysine and glutamic acid residues were reversed in the same sequence, no 
helical content was observed. Schultz and co-workers later reported the synthesis of short 
Taylor
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peptides that were designed to bridge the i, i +7 residues through a single intramolecular 
disulfide bond (Figure 2.2) to stabilize two turns of an α-helical peptide.16 Although the 
results demonstrated the utility of using disulfide bonds to stabilize helical conformations 
in short peptides, disulfides have both multiple conformations that can affect the nature of 
the staple and are not stable in the intracellular environment of the cytosol. While these 
studies began to demonstrate the importance of stapling tactics to stabilize peptide confor-
mations, a major advancement in the field came with the advent of all-hydrocarbon sta-
pling.  
All Hydrocarbon Peptide Stapling 
 
The first example of hydrocarbon stapling was carried out by Blackwell and Grubbs 
employing allylic serine ethers, spaced in an i, i + 4 fashion, within a peptide followed by 
macrocyclization via ring-closing metathesis to form a stabilized helix (Figure 2.3).17  
  
 
Figure 2.3. First Examples of Helix-Stabilization by Macrocyclization 
RCM
RCM
Verdine
Grubbs
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Verdine and co-workers recognized the significance of this discovery and began preparing 
new α,α-disubstituted amino acids containing an olefin side-chain (Figure 2.3).18 After op-
timizing both the linker length and the stereochemical configuration, the requisite unnatural 
residues were introduced into peptides by solid-phase peptide synthesis, then macrocy-
clization with  ring-closing metathesis afforded the stapled peptides with increased helicity. 
This strategy has now reduced to practice the ability to not only to stabilize helical struc-
tures, but also the induction of unstructured peptides into their respective helical confor-
mations. All-hydrocarbon stapling provides the ability to predict a helical structure from 
the linear sequence of amino acids by using crystal structures of protein-protein interac-
tions and, in turn, has permitted the rational design of bioactive peptides endowed with 
many of the favorable properties of the protein. In many cases, these stapled peptides show 
improved potency, resistance to proteolytic degradation and improved cellular absorption, 
opening the potential to target intracellular processes. 
Alternative Tactics of Peptide Stapling 
An expanding repertoire of peptide stapling techniques has started to emerge.19 These 
tactics can be split into two categories (Figure 2.4); first is an intramolecular stapling strat-
egy, which employs the functionality of side-chains within the peptide to form the macro-
cycle. On the other hand, a bicomponent strategy can be used to link the side-chains of 
peptides combined with an exogenous component to bridge the peptide into a macrocyclic 
conformation. While both strategies have been effective for the construction of stapled 
peptides, these tactics do not permit the removal of the inserted staple (i.e. unstapling) 
without significantly disrupting the peptide structure. 
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Figure 2.4. Tactics Developed for Peptide Stapling  
 
Nature’s Example of Peptide Unstapling 
The value of stapled peptides has been well established by the number of reported bio-
active stapled peptides, featuring high potency and predictable properties. However within 
this dissertation a question that must be asked is: what is the value of peptide unstapling? 
In chapter 1 we presented the release of restricted conformations to permit kinetic meas-
urements for ultrafast structural transitions within peptides. Another advantage of manip-
ulating conformation in situ may hold a valuable pharmacological role. Turning to an ex-
ample from nature, β-defensin (Figure 2.5) is a 20-residue peptide stapled by three disulfide 
bonds that is produced by epithelial cells throughout the body. This stapled peptide has 
evolved to stand guard between you and the microbial world. However, initial biological 
testing of β-defensin has indicated the stapled conformation to be a poor antibiotic against 
both Gram positive and negative bacteria. It was later discovered that upon treatment of 
PeptidePeptide
Peptide Peptide Peptide Peptide
PeptidePeptide
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Figure 2.5. β-Defensin Employs Unstapling to Release Active Pharmacophore 
 
β-defensin with thioredoxin reductase results in reduction of the disulfide bonds, effec-
tively unstapling the peptide, which in turn changes the conformation and reveals a potent 
antibiotic.20 It was subsequently determined that the pharmacophore of the molecule was 
contained within the center of the stapled conformation (last 7 C-terminal residues, Figure 
2.5), thus rendering it inactive toward bacteria. However, when the antibacterial properties 
are required, nature has evolved an unstapling mechanism to release the active component. 
Unstapling: Development of the s-Tetrazine Stapling and Unstapling Protocol 
 
Given the critical role of conformation in peptides and proteins, our focus shifts to s-
tetrazine: The question asked is, can s-tetrazine be used as a stapling motif? Additional 
questions include: can conditions be developed that permit dichlorotetrazine introduction 
into unprotected peptides under aqueous conditions? Also of importance, what are the lim-
itations of the ring sizes that could be formed or the amino acid side chain compatibility? 
And most important, as a peptide staple, would s-tetrazine permit restricted peptides to be 
photochemically unstapled? 
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A Model System for the Development of s-Tetrazine Stapling and Unstapling 
In pursuit of suitable conditions that would permit the incorporation of dichlorotetrazine 
into unprotected peptides, a model compound 32 (Scheme 2.1) was designed to contain 
many of the reactive side-chains found within peptides and was prepared by standard 
Fmoc-based solid-phase peptide synthesis.21 A series of solvents, denaturants and pH levels 
were investigated for the reaction of peptide 32 with dichlorotetrazine to form 33.  
 
 
Scheme 2.1. Stapling, Unstapling and Regeneration of the Native Peptide 
 
Separation of the phases containing the two reactants was discovered to permit excellent 
chemoselective control for the sulfhydryl addition into the highly electrophillic 
dichlorotetrazine. Mild acidic conditions (pH 5) provided the best chemoselective control 
in the reaction; lower pH slowed the rate of tetrazine transfer while 33 revealed instability 
with pH enviroments that were greater than pH 9. Denaturants were also investigated; the 
addition of guanidine hydrochloride, often used to denature peptides, did not affect the 
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yield of the model reaction and thus was not included in the phase-transfer cocktail to assist 
the purification efficiency. A denaturant, such as guanidine hydrochloride, however may 
play a more significant role in breaking the secondary structure and minimizing aggrega-
tion when exploring larger peptide systems. The addition of a reducing agent to the reaction 
solution to prevent disulfide formation was also considered, however tris(2-carboxy-
ethyl)phosphine (TCEP) reacted with dichlorotetrazine during the course of the reaction. 
In addition tris(2-carboxyethyl)phosphine (TCEP) will also reduce S,S-tetrazine motif to 
the S,S-dihydrotetrazine congener and thus was not used in the reaction. In the event that 
disulfide bond formation becomes problematic, immobilized TCEP can be used to reduce 
the disulfide and then removed by filtration just prior to the addition of dichlorotetrazine. 
The best phase-transfer protocol employed peptide 32 with the conditions listed in Scheme 
2.1 to provide 33 with minimal side-products and in good yield after purification. Follow-
ing isolation, 33 was subjected to steady-state irradiation under UV-A lamps to remove the 
tetrazine chromophore and thus releasing the restricted conformation affording the dithio-
cyanate peptide 34 in near quantitative yield. 
Next a mild protocol to remove the nitriles from the thiocyanate groups in 34 was de-
veloped to regenerate the native disulfhydryl peptide 32 (Scheme 2.1). Early studies by 
Catsimpoolas22-23 and Patchorn24 had demonstrated respectively cyanylation of cysteine 
using an activated arylthiocyanate, and cleavage of the disulfide of cystine with sodium 
cyanide; both furnished the thiazolamine product 35 (Figure 2.5). These observations sug-
gested that the nitriles could be removed via intramolecular cyclization with cysteine, en-
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visioned to be mechanistically analogous to a native-chemical ligation25 (Figure 2.6). In-
deed, treatment of peptide 34 with cysteine in pH 8 buffer regenerated peptide 32 along 
with thiazolamine 35 (Scheme 2.1) readily isolated from the reaction mixture.   
 
 
Figure 2.6. Proposed Mechanism of Nitrile Removal from the Thiocyanates 
 
s-Tetrazine Stapling Compatibility with Various Peptide Substrates 
 
Encouraged by the results of the model study, we next explored the incorporation of 
dichlorotetrazine into a variety of peptide substrates employing various spacing between 
the cysteine residues while also testing the compatibility all of the coded amino acids. To 
this end, stapled tetrazine macrocycles 36-43 were prepared (Scheme 2.2) employing the 
developed protocol and then isolated after reverse-phase chromatography. Minor amounts 
of disulfide and dimeric products were separated from the reaction mixture while oligi-
meric products became increasing problematic as the ring sizes of the peptides became 
larger; however separation of the desired monomer was achieved in every case. Minor 
amounts of oxidation of the methionine side chain was observed. Additionally, previous 
solid-phase peptide synthesis of tetrazine peptides containing the arginine side-chain had 
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resulted in decomposition (Scheme 1.4). Pleasingly, both peptides containing methionine 
and arginine side-chains were stable to this protocol with s-tetrazine in solution after iso-
lation under buffered conditions.  
 
 
Scheme 2.2. s-Tetrazine Stapled Peptides Prepared by Phase-Transfer Conditions 
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Photochemical Unstapling of s-Tetrazine Stapled Peptides 
 
Pleasingly, the photochemical release of the s-tetrazine staple under steady-state irradi-
ation proved feasible. First, tetrazine peptides 36-38 were subjected to the identical condi-
tions employed in Scheme 2.1; however only small amounts of product were observed in 
these cases. Next, a screen for optimal photochemical conditions entailed a variety of sol-
vents, additives and wavelengths. Unfortunately, photochemical side-products were still 
observed in the crude reactions mixtures. However, in the best case scenario methanol was 
used as the solvent and UV-B lamps (λMax = 312 nm) as the light source. Under these 
conditions, the unstapled products 44-46 could be separated from the complex mixtures, 
with yields ranging from 25-46% (Scheme 2.3). Undeterred, we next investigated the effect 
of the reaction temperature and the relationship towards the formation of side-products. To  
  
 
Scheme 2.3. Photochemical Unstapling Under Initial Conditions  
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control the temperature of the reaction within the Rayonet photoreactor, an apparatus was 
built from a glass bottle and connected to a circulating chiller (Figure 2.7). Then 37 was 
dissolved in methanol, the solution transferred to a sealed microwave vial and transferred 
to the apparatus with the contents submersed in the cooling  
 
Figure 2.7. (A) Apparatus employed to Conduct Temperature Controlled Photolysis (B) 
UV-vis of Different Cooling Solutions 
 
solution. The reactant 37 was irradiated under UV-B lamps at 1ºC for seven days to furnish 
45 in 85% yield by LC-MS. Encouraged by the result, that the reaction proceeded without 
the formation of side-products, although the conditions required one week to reach com-
pletion. Analysis of the cooling solution by UV-vis indicated strong absorbance at lower 
wavelengths. Comparison with newly prepared cooling solution suggested an algae was 
preventing the transmission of light into the sample (Figure 2.7). The cooling solution was 
changed and the identical reaction was performed again. Now the starting material 37 was 
consumed after only four hours providing 45 albeit present within a complex mixture.   Iso-
lation afforded 45 in 36% yield after purification. Increasing the transmission of light into 
0
5
10
15
20
25
30
35
200 250 300 350 400 450 500 550 600
O
d
Wavelength (nm)
UV-vis of Cooling Solution
Old cooling solution
New cooling solution
61 
 
the reaction had now resulted in additional side products! While restricting the transmission 
of light with algae revealed that the reaction was capable of forming 45 as a single product, 
the results suggested a least two possible photochemical mechanisms were occurring with 
reaction conditions B (Scheme 2.4). Postulating that one mechanism involved a triplet- 
 
 
Conditions Cooling Solution Time Yield 
A contained algae 7 days 85% 
B new ethylene glycol/water 4 hours 36% 
 
Scheme 2.4. Temperature Controlled Photolysis  
 
state radical leading to the formation of the side-products; while another led to the for-
mation of 45 which does not contain long-lived radical intermediates. The latter was also 
supported by the photophysical experiments described in Chapter 1. Reasoning that oxygen 
gas would suppress side-reactions arising from a triplet-state radical, solutions containing 
peptides 36-38, 40, 42 were sparged with oxygen prior to photochemical irradiation. Under 
these conditions exclusive formation of the unstapled peptides 44-48 (Scheme 2.5) oc-
curred when the photolysis was conducted with UV-B lamps in the presence of oxygen. 
For peptides containing tryptophan and methionine residues (cf. 39, 41, 42), additional re-
activity was observed under the oxygen conditions; nonetheless the dithiocyanate counter-
part 48 is provided as an example that could be isolated in 38% yield after purification. In 
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the end, conditions were defined that permitted the tetrazine macrocycle to be readily un-
stapled photochemically in situ to yield the unconstrained linear dithiocyanate peptides 44-
48, which were in turn converted to their native structures employing cysteine for nitrile 
removal (Figure 2.6). 
 
Scheme 2.5. Oxygenated Photolysis and Effective Unstapling of s-Tetrazine 
 
Stapling Peptides with Proximal Lysine Residues 
 
Given the successful completion of the initial goals with regards to stapling and unsta-
pling peptides with s-tetrazine, the question we now ask: can the side chains of other amino 
acids be used to staple peptides and, in turn, would those structures undergo photochemical 
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unstapling? Envisioning a strategy that would employ unprotected peptides containing only 
a single cysteine sulfhydryl followed by introduction of s-tetrazine would generate Cl,S-
tetrazine peptides. Importantly, changing the nature of the buffer, the Cl,S-tetrazine pep-
tides, might be inclined to undergo macrocyclization with the amino group of a proximal 
lysine side-chain to form an S,N-tetrazine stapled peptide. By seeking to isolate the Cl,S-
tetrazine product, this strategy could also be used for macrocyclization strategies with other 
peptide side-chains and/or provide access to peptide/protein S,S-tetrazine conjugates via a 
separate cysteine residue of a different molecule. Our focus thus turned to stapling and 
unstapling employing proximal lysine side chains.  
An investigation was initiated to determine suitable conditions that would permit un-
protected peptides, containing a single cysteine residue, to be functionalized with s-te-
trazine in aqueous buffer, thus arriving at the Cl,S-tetrazine peptide. A model peptide 49 
was constructed by manual Fmoc-based solid-phase peptide synthesis (SPPS) and evalu-
ated under several conditions. First, treatment of 49 with the aforementioned biphasic pro-
tocol resulted in the formation of symmetrical homodimer. As such, the conditions were 
changed to a monophasic system. To this end, peptide 49 was dissolved in a pH 5 monoso-
dium phosphate buffer.  In a separate flask three equivalents of dichlorotetrazine was dis-
solved in acetonitrile. Upon adding the aqueous solution of peptide to the acetonitrile so-
lution, and stirring for one minute, 50 was obtained in 71% yield after reverse-phase chro-
matography (Scheme 2.6). Notably, the Cl,S-tetrazine peptide 50 is stable in the presence 
of protonated amines and in acidic buffers (< pH 6). With 50 in hand, conditions to effect  
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Scheme 2.6. Synthesis of Cl,S-Tetrazine Peptide 50 and S,N-Tetrazine Peptide 51 
 
macrocyclization with the proximal lysine side-chain were examined by changing the pH 
of the buffer. Evaluation of a tris-buffer system at pH 8.5 was not compatible, finding that 
the amine of the tris buffer reacted with tetrazine faster than the lysine side-chain. The 
buffer system was therefore changed to a phosphate buffer (pH 8.5). After stirring for five 
minutes 51 resulted with minimal reactivity toward the buffer/solvent. During the course 
of this reaction some S,N-dimer had also formed. The reaction was therefore conducted at 
a lower concentration (500 μM) of the peptide substrate 50.  These conditions facilitated 
the optimal addition of the lysine side-chain into tetrazine to furnish 51 in 83% yield after 
purification by reverse-phase chromatography. Thus, the model system 49 supports the 
strategy of using the Cl,S-tetrazine intermediate 50 to gain access to the S,N-tetrazine mac-
rocycle 51 with the amino side-chain of lysine. 
Unstapling the S,N-Tetrazine Peptide 51 
 
Turning our attention to the photochemical unstapling of 51, questions had arisen re-
garding the effect of the nitrogen atom on the photochemical properties of the tetrazine 
chromophore. The previously developed photochemical conditions for unstapling S,S-te-
trazine peptides were applied to a solution of 51 in methanol and sparged with oxygen gas 
prior to irradiation with UV-B lamps (Scheme 2.7). The reaction resulted in a complex 
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mixture of products.  Analysis by proton NMR and LC-MS suggested formation of a meth-
anol adduct as one of the products. Speculating that the cyanamide functionally of 52 may 
not be stable in nucleophilic solvents, we turned to water as a solvent to trap potentially 
the envisioned cyanamide as the urea. A second reaction was conducted with 51 dissolved 
in water [100μM], in a heavy-walled Pyrex tube and sparged with oxygen gas. The contents 
 
 
Scheme 2.7. Photochemical Unstapling of S,N-Tetrazine Peptide 51 
 
were then irradiated with a single UV-B lamp to restrict the transmission of light into the 
sample. After four days, 51 was consumed with only one major product observed in the 
solution. LC-MS analysis indicated the mass of the product to be similar to 53 (M + H, m/z 
= 359), however after comparing the NMR spectra of the product from the photolysis with 
an authentic sample of 53, prepared by solid-phase peptide synthesis, found that the two 
samples did not match. It is clear that the addition of a nitrogen atom to the s-tetrazine ring 
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affects the photochemical properties of the molecule. Transient absorption and phospho-
rescence measurements will need to be conducted to further elucidate the photophysics of 
these molecules.  Such work is outside the scope of this thesis.  
Bioconjugate Reaction Exploiting the s-Tetrazine Staple 
 
A significant advantage of the s-tetrazine staple is the reactivity of the incorporated te-
trazine to introduce probes via inverse electron demand Diels-Alder reactions.26 To demon-
strate this feature, fluorescein dye 54 was prepared and combined with stapled peptide 42 
to obtain a diastereomeric mixture of the fluorescein labeled peptide 55 (Scheme 2.8). 
Thus, tetrazine staples hold the promise of a dual role: confining peptide conformation and 
introducing photophysical and other potential probes.27-29 
 
 
Scheme 2.8. s-Tetrazine Stapled Peptides Provide Effective Bioconjugate Handle 
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Stapling and Unstapling the Protein Thioredoxin with s-Tetrazine 
 
The tetrazine stapling and unstapling protocol was next extended to proteins. Thiore-
doxin (Trx) was selected as a model protein, which contains a single, solvent exposed 
disulfide bond. The biphasic protocol used to staple peptides was ineffective for thiore-
doxin due to the formation of insoluble forms of the protein upon mixing with organic 
solvent. A new protocol was thus developed for thioredoxin employing a monophasic aque-
ous buffer. The new procedure entailed first reduction of the thioredoxin disulfide bond 
with immobilized TCEP, which was then removed by filtration. The reduced thioredoxin, 
in a pH 5 acetate buffer, was then stirred with a pre-mixed solution of dichlorotetrazine in 
dimethyl sulfoxide (acetate buffer/dimethyl sulfoxide; 50:1) with an overall concentration 
of protein at 20 μM (Scheme 2.9).  After one minute, 56 was formed as 
 
 
Scheme 2.9. Stapling the Protein Thioredoxin with s-Tetrazine 
 
 
indicated by MALDI-TOF-MS (m/z = 11757.782). Purification was achieved with a de-
salting column. The Bradford assay is a protocol that quantifies microgram quantities of 
protein by measuring an absorbance shift upon binding of coomassie blue dye complexed 
Native-Trx 56
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to the protein.30 The Bradford method determined an 88% yield for the reaction, while 
reverse-phase C4-LC-MS chromatography indicated 90% purity for the sample, thus illus-
trating that the stapling of thioredoxin with s-tetrazine proceeds with high efficiency to 
furnish 56. 
With the 56 in hand, in situ, photolysis under an ambient atmosphere with UV-B lamps 
was conducted to effect unstapling of the s-tetrazine adduct (Scheme 2.10). After one hour 
MALDI-TOF-MS revealed the loss of N2, but also partial loss of nitrile groups from the 
thiocyanates. To completely remove the nitriles, a solution of cysteine was added. After 
four hours the reaction solution was removed via centrifugal filtration. Addition of 
Ellman’s reagent then furnished the disulfide bond of the protein 57, again as observed by 
MALDI-TOF-MS. Bradford’s method revealed a 73% yield for the reaction with C4-LC-
MS chromatograms indicating a 52% purity for the regenerated protein 57.   
 
 
Scheme 2.10. Unstapling the Protein Thioredoxin Containing s-Tetrazine with UV-B Lamps 
 
To interrogate the regenerated protein as the native form, bioactivity measurements 
were conducted. Evaluation of the enzymatic activity for the thioredoxin compounds was 
56 57
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examined using insulin as the substrate and dithiothreitol as the electron donor system 
(Figure 2.8). In this assay, dithiothreitol reduces thioredoxin and the reduced protein then  
 
Figure 2.8. Bioactivity Measurement for Regenerated Thioredoxin Resulting from UV-B 
Photolysis 
 
reduces the disulfide bonds of insulin. The reduction of insulin is monitored at 650 nm by 
an increase in turbidity for the solution. The bioactivity measurements involve a change in 
absorbance at 650 nm per minute as a function of protein concentration again determined 
by the Bradford method. The regenerated protein 57 did not show substantial increase in 
the catalytic turnover for the reduction of insulin when compared to the 56. However, the 
regenerated protein 57 does remain reactive towards electrophiles such as dichlorotetrazine 
when resubjected to the described stapling conditions (Scheme 2.9). In addition, native 
thioredoxin, without incorporation of s-tetrazine, was treated with the identical photochem-
ical conditions used to unstaple 56 (Scheme 2.11) only to find similar loss of biological 
activity. This finding suggested that the photochemical conditions were not compatible 
with this biological system. 
0
10
20
30
40
50
60
70
80
0 10 20 30 40 50 60
(Δ
m
A
U
/m
in
)
Protein (ug/mL)
Enzyme Activity for Thioredoxin Products 
Native Trx
Tetrazine Trx
Regenerated Trx
70 
 
 
Scheme 2.11. Control Reaction for the Photolysis of Thioredoxin with UV-B Lamps 
 
New Photochemical Conditions for Unstapling s-Tetrazine Thioredoxin 
 
New photochemical conditions were developed to permit the unstapling and regenera-
tion of the native protein thioredoxin. Reasoning that the loss of biological activity was 
due, in part, to the higher energy wavelengths of the UV-B lamps (λMax = 312 nm), we 
turned to laser-induced photolysis using a Nd:YAG flashlamp with a 355 nm wavelength. 
In addition to the lower energy wavelength, the flashlamp contains a delay between each 
pulse, which may permit relaxation of other possible excited states prior to a subsequent 
excitation pulse. To this end, s-tetrazine thioredoxin (56) was dissolved in degassed 10 mM 
PBS, 100 mM NaCl, pH 7 at an overall concentration of 10 μM, and irradiated with the 
355 nm flashlamp (Scheme 2.12). After one hour, MALDI-TOF-MS did not detect 56. 
Importantly, a new mass corresponding to the loss of nitrogen gas was observed suggesting 
thioredoxin containing two thiocyanates had been formed. The reaction solution was then 
treated with 10 mM cysteine in 500 mM phosphate buffer system (pH 7.8) to achieve a 1 
mM overall concentration of cysteine and a 9 μM concentration for the protein which was 
allowed to stand at 5ºC for 16 hours. The reaction solution was then removed by centrifugal  
57Native-Trx
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Scheme 2.12. Biocompatible Unstapling Conditions with Laser-Induced Photolysis 
 
filtration and analyzed by MALDI-TOF-MS to find both the loss of the nitriles from the 
thiocyanates and the molecular mass of regenerated thioredoxin protein. 
Bioactivity measurements were then conducted to evaluate 57 resulting from the 355 
nm flashlamp photolysis experiment. The insulin reduction assay was conducted, as de-
scribed in Figure 2.6, with native thioredoxin, 56 and 57 from Scheme 2.12. The protein 
concentrations were determined by the Bradford method with the assays run in triplicate. 
Analysis of the data revealed that although the bioactivity of 57 was significantly less than 
 
 
Figure 2.9. Bioactivity Measurement for Regenerated Thioredoxin Resulting from Laser-
Induced Photolysis 
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that of the native thioredoxin, 57 did however display an increase in activity when com-
pared to protein containing tetrazine 56 (Figure 2.9). Pleasingly, this result indicates that 
some of the native protein was regenerated with the flashlamp conditions for photolysis. 
This encouraging result demonstrates that these conditions are at least in part compatible 
with biological systems. 
To summarize, conditions have developed and validated for the incorporation of s-te-
trazine employing cysteine sulfhydryl groups of unprotected peptides and the protein thi-
oredoxin. The biphasic reaction enables the construction of macrocyclic peptides, with a 
wide range of functionally and ring topology, bridging from one to 27 amino acid residues 
adjoining cysteines. Importantly, the stapled conformations can be released photochemi-
cally to their thiocyanate counterparts, and in turn the resulting thiocyanates removed to 
regenerate the native peptide. To the best of our knowledge s-tetrazine comprises the first 
example of a readily removable peptide staple. Finally, the stapling and unstapling protocol 
has been extended to include thioredoxin as an example of a protein with an incorporated 
s-tetrazine construct that can also serve a useful role in conjugation strategies. 
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Experimental for Chapter 2 
 
 
Peptide 32. was constructed by SPPS from 1.0 mmol loaded 2-chloro-chlorotrityl resin. 
Removal of the peptide from resin was conducted with cocktail A (20 mL) following the 
general cleavage method. The peptide was purified by reverse-phase HPLC (5 - 15% or-
ganic over 5 min) to give 360 mg (45% •2 TFA salt form) of a white amorphous powder 
after lyophilization: HRMS (ES) found m/z 569.2067 [(M+H)+; calcd for C28H37N6O9S2: 
569.2063]; 1H NMR (500 MHz, D2O) δ ppm 1.38 - 1.48 (m, 2 H) 1.68 (quin, J = 7.3 Hz, 2 
H) 1.72 - 1.81 (m, 1 H) 1.85 - 1.94 (m, 1 H) 2.19 (q, J = 7.3 Hz, 2 H) 2.55 (t, J = 7.3 Hz, 2 
H) 2.90 - 3.02 (m, 6 H) 3.89 (t, J = 4.9 Hz, 2 H) 4.14 (t, J = 6.5 Hz, 1 H) 4.32 (dd, J = 8.9, 
5.2 Hz, 1 H) 4.52 (t, J = 5.4 Hz, 1 H) 4.58 (t, J = 6.2 Hz, 1 H) 4.61 (t, J = 6.30 Hz, 1 H); 
13C NMR (126MHz, D2O) δ 176.6, 176.2, 171.6, 171.5, 171.4, 169.4, 61.1, 55.8, 55.7, 
55.6, 53.4, 52.4, 39.3, 30.3, 29.4, 26.3, 26.1, 25.5, 25.4, 22.2; IR (KBr, cm-1) 3425 (br), 
3286 (br), 3077 (br), 2950 (br), 1682 (s), 1628(s), 1535 (m), 1429 (m), 1207 (s), 1132 (s). 
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Peptide SI-4. was constructed by SPPS from 0.10 mmol loaded Rink amide resin. Removal 
of the peptide from resin was conducted with cocktail A following the general cleavage 
method. The peptide was purified by reverse-phase HPLC (5 - 35% organic over 12 min) 
to give 46.4 mg (65% • TFA salt form) of a white amorphous powder after lyophilization: 
HRMS (ES) Found m/z 606.2378 [(M+H)+; calcd for C23H40N7O8S2: 606.2380]; 
1H NMR 
(500MHz ,DMSO-d6) δ 8.55 (br. s., 1 H), 8.52 (d, J = 7.3 Hz, 2 H), 8.08 (d, J = 7.3 Hz, 1 
H), 7.74 (d, J = 7.5 Hz, 1 H), 7.06 (s, 2 H), 7.02 (s, 2 H), 4.78 (q, J = 6.9 Hz, 1 H), 4.44 
(dd, J = 5.4, 11.3 Hz, 1 H), 4.27 (dd, J = 3.8, 8.5 Hz, 1 H), 4.23 (dd, J = 4.8, 8.1 Hz, 1 H), 
4.21 (dd, J = 4.8, 8.3 Hz, 1 H), 4.11 (quin, J = 7.2 Hz, 1 H), 3.71 (t, J = 6.3 Hz, 2 H), 3.55 
(d, J = 5.5 Hz, 1 H), 2.82 (d, J = 4.6 Hz, 1 H), 2.83 (dd, J = 4.8, 13.7 Hz, 1 H), 2.76 (br. s., 
1 H), 2.77 (dd, J = 8.5, 15.0 Hz, 1 H), 2.75 (br. s., 1 H), 2.71 (dd, J = 7.1, 16.4 Hz, 1 H), 
2.42 (dd, J = 6.9, 16.2 Hz, 1 H), 2.11 - 2.00 (m, 2 H), 1.99 - 1.92 (m, 1 H), 1.92 - 1.84 (m, 
2 H), 1.23 (d, J = 7.1 Hz, 3 H), 0.92 (d, J = 6.7 Hz, 3 H), 0.89 (d, J = 6.7 Hz, 3 H); 13C 
NMR (126 MHz, DMSO-d6) δ 174.1, 171.9, 171.7, 169.2, 168.9, 167.9, 60.2, 57.2, 55.5, 
54.9, 48.3, 47.8, 47.0, 35.6, 29.9, 29.1, 26.3, 25.8, 24.5, 18.4, 18.0, 17.7;  IR (KBr, cm-1) 
3332(br), 3067(m), 2974(m), 1664(vs), 1525(m), 1451(w), 1200(m), 1132(w).  
 
Peptide SI-5. was constructed by SPPS from 0.10 mmol loaded Rink amide resin. Removal 
of the peptide from resin was conducted with cocktail A following the general cleavage 
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method. The peptide was purified by reverse-phase HPLC (5 - 35% organic over 15 min) 
to give 39.2 mg (46% • TFA salt form) of a white amorphous powder after lyophilization: 
HRMS (ES) Found m/z 742.3011 [(M+H)+; calcd for C30H48N9O9S2: 742.3016]; 
1H NMR 
(500MHz ,DMSO-d6) δ = 9.37 (br. s., 1 H), 8.82 (d, J = 7.7 Hz, 1 H), 8.31 (br. t, J = 5.6 
Hz, 2 H), 8.22 (d, J = 7.1 Hz, 1 H), 8.18 (t, J = 5.0 Hz, 1 H), 8.10 (d, J = 7.1 Hz, 2 H), 7.73 
(d, J = 8.1 Hz, 1 H), 7.23 (s, 1 H), 7.05 (d, J = 8.1 Hz, 2 H), 6.97 (s, 1 H), 6.71 - 6.67 (m, 
J = 8.1 Hz, 2 H), 4.49 (dd, J = 6.7, 13.7 Hz, 1 H), 4.41 (dd, J = 7.3, 13.1 Hz, 1 H), 4.23 
(dd, J = 7.1, 14.3 Hz, 1 H), 4.19 (dd, J = 8.1, 15.7 Hz, 1 H), 4.04 (t, J = 5.9 Hz, 1 H), 3.85 
(dd, J = 5.7, 16.6 Hz, 1 H), 3.77 (d, J = 5.4 Hz, 6 H), 3.75 (dd, J = 5.5, 17.0 Hz, 1 H), 3.01 
(dd, J = 5.2, 14.3 Hz, 1 H), 2.85 - 2.74 (m, 4 H), 2.75 - 2.65 (m, 1 H), 2.40 (t, J = 8.4 Hz, 
1 H), 1.58 (quind, J = 6.6, 13.3 Hz, 1 H), 1.45 (t, J = 7.2 Hz, 2 H), 1.22 (d, J = 7.1 Hz, 3 
H), 0.87 (d, J = 6.7 Hz, 3 H), 0.82 (d, J = 6.5 Hz, 3 H); 13C NMR (126MHz ,DMSO-d6) δ 
174.0, 171.7, 169.5, 169.3, 169.2, 169.0, 168.9, 168.3, 156.6, 130.5, 124.7, 115.4 (2C), 
55.1, 54.9, 53.6, 50.9, 48.7, 42.0, 42.0, 42.0, 41.0, 36.2, 26.2, 26.2, 24.2, 23.1, 21.6, 17.6; 
IR (KBr, cm-1) 3306(br), 2957(m), 1661(vs), 1518(s), 1202(m), 1136(w). 
 
Peptide SI-6. was constructed by SPPS from 0.10 mmol loaded Rink amide resin. Removal 
of the peptide from resin was conducted with cocktail A following the general cleavage 
method. The peptide was purified by reverse-phase HPLC (5 - 35% organic over 15 min) 
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to give 43.8 mg (50% • TFA salt form) of a white amorphous powder after lyophilization: 
HRMS (ES) Found m/z 770.3336 [(M+H)+; calcd for C40H487N7O7S2: 770.3336]; 
1H NMR 
(500 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.67 (d, J = 8.0 Hz, 1H), 8.18 (t, J = 5.8 Hz, 1H), 
8.14 (q, J = 5.5 Hz, 2H), 8.09 (d, J = 7.2 Hz, 1H), 8.06 – 7.98 (m, 3H), 7.69 (d, J = 8.4 Hz, 
1H), 7.22 (s, 1H), 7.03 (d, J = 8.5 Hz, 2H), 6.94 (s, 1H), 6.69 (d, J = 8.5 Hz, 2H), 4.47 
(ddd, J = 8.2, 5.3 Hz, 1H), 4.38 (ddd, J = 8.3, 5.1 Hz, 1H), 4.28 – 4.13 (m, 2H), 4.02 – 3.93 
(m, 1H), 3.83 (dd, J = 16.6, 5.8 Hz, 1H), 3.79 – 3.68 (m, 4H), 2.99 (dd, J = 14.2, 5.4 Hz, 
1H), 2.79 (dd, J = 13.8, 8.5 Hz, 1H), 2.68 (s, 0H), 2.48 – 2.40 (m, 2H), 2.37 (t, J = 8.0 Hz, 
1H), 2.29 (t, J = 8.0 Hz, 1H), 2.08 – 1.74 (m, 4H), 1.58 (dt, J = 13.4, 6.7 Hz, 1H), 1.45 (dd, 
J = 8.4, 6.2 Hz, 2H), 1.21 (d, J = 7.1 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H), 0.83 (d, J = 6.5 Hz, 
3H); 13C NMR (126 MHz, DMSO) δ 173.9, 171.7, 170.7, 170.5, 169.1, 168.9, 168.8, 168.1, 
156.5, 130.4, 124.7, 115.3, 53.6, 51.7, 51.5, 50.8, 48.4, 42.0, 41.9, 41.0, 36.8, 36.5, 36.1, 
24.2, 23.0, 21.6, 20.3, 20.2, 17.6; IR (KBr, cm-1) 3309(br), 2956(m), 1662(vs), 1515(s), 
1202(m), 1136(w). 
 
Peptide SI-7. was constructed by SPPS from 0.10 mmol loaded Rink amide resin. Removal 
of the peptide from resin was conducted with cocktail B following the general cleavage 
method. The peptide was purified by reverse-phase HPLC (5 - 60% organic over 12 min) 
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to give 45.6 mg (44% • TFA salt form) of a white amorphous powder after lyophilization: 
HRMS (ES) Found m/z 933.4111 [(M+H)+; calcd for C45H61N10O8S2: 933.4115]; 
1H NMR 
(500 MHz, DMSO-d6) δ 10.81 (s, 1H), 8.63 (d, J = 8.0 Hz, 1H), 8.33 (d, J = 8.3 Hz, 1H), 
8.28 (d, J = 8.1 Hz, 1H), 8.17 (d, J = 8.0 Hz, 1H), 8.15 (s, 2H), 7.99 (d, J = 8.0 Hz, 1H), 
7.85 (d, J = 8.0 Hz, 1H), 7.71 (s, 2H), 7.66 (d, J = 7.9 Hz, 1H), 7.39 (s, 1H), 7.36 – 7.23 
(m, 5H), 7.15 (d, J = 2.4 Hz, 1H), 7.11 (dt, J = 4.9, 1.7 Hz, 2H), 7.06 – 7.01 (m, 3H), 7.01 
– 6.94 (m, 1H), 4.68 (ddd, J = 8.4, 5.8 Hz, 1H), 4.54 (ddd, J = 8.6, 4.3 Hz, 1H), 4.42 (q, J 
= 6.5 Hz, 1H), 4.36 (dp, J = 10.5, 5.6, 4.9 Hz, 2H), 4.23 (dd, J = 7.9, 4.3 Hz, 1H), 4.17 – 
4.10 (m, 1H), 4.03 (dd, J = 6.5, 4.5 Hz, 1H), 3.11 – 3.02 (m, 2H), 2.96 (dd, J = 14.0, 7.8 
Hz, 1H), 2.92 – 2.81 (m, 2H), 2.81 – 2.72 (m, 2H), 2.72 – 2.64 (m, 2H), 2.54 (t, J = 7.9 Hz, 
1H), 2.29 (t, J = 8.5 Hz, 1H), 2.02 (t, J = 8.6 Hz, 1H), 1.63 (td, J = 13.3, 6.9 Hz, 1H), 1.53 
– 1.36 (m, 3H), 1.13 (p, J = 7.4 Hz, 2H), 1.05 (d, J = 6.3 Hz, 3H); 13C NMR (126 MHz, 
DMSO) δ 171.8, 171.4, 171.3, 170.3, 169.8, 168.8, 168.0, 137.5, 136.1, 134.8, 129.5, 
129.5, 129.2, 128.5, 127.9, 127.2, 127.2, 126.1, 123.9, 120.8, 118.6, 118.1, 111.2, 109.7, 
66.3, 58.3, 54.6, 54.5, 54.0, 53.3, 53.2, 52.1, 38.7, 37.3, 37.3, 31.3, 28.7, 26.7, 26.6, 26.1, 
22.0, 19.5; IR (KBr, cm-1) 3281(br), 2928(w), 1671(s), 1523(m), 1202(m). 
 
Peptide SI-8. was constructed by SPPS from 0.10 mmol loaded Rink amide resin. Removal 
of the peptide from resin was conducted with cocktail A following the general cleavage 
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method. The peptide was purified by reverse-phase HPLC [eluent water/MeCN/AcOH 
(85:10:5) and MeCN (organic) buffered with 0.1%TFA] (5 - 40% organic over 15 min) to 
give 49.5 mg (23% • 4 TFA salt form) of a white amorphous powder after lyophilization: 
MALDI-TOF Found m/z 1694.004 [(M+H)+; calcd for C79H125N18O19S2: 1693.880]; 
1H 
NMR (500 MHz, DMSO-d6) δ 12.45 (s, 1H), 9.21 (d, J = 15.0 Hz, 2H), 8.43 (d, J = 7.5 
Hz, 1H), 8.31 (dd, J = 8.2, 3.8 Hz, 2H), 8.16 – 7.87 (m, 13H), 7.85 (d, J = 7.9 Hz, 2H), 
7.81 – 7.62 (m, 13H), 7.39 (s, 1H), 7.25 – 7.18 (m, 4H), 7.18 – 7.12 (m, 1H), 7.06 (s, 1H), 
7.01 (d, J = 8.5 Hz, 2H), 6.93 (d, J = 8.3 Hz, 2H), 6.63 (d, J = 8.3 Hz, 2H), 6.60 (d, J = 8.5 
Hz, 2H), 5.00 (d, J = 4.4 Hz, 1H), 4.62 (dq, J = 7.9, 4.7 Hz, 1H), 4.57 (q, J = 7.1 Hz, 1H), 
4.41 (q, J = 7.2 Hz, 2H), 4.38 – 4.23 (m, 6H), 4.20 (q, J = 7.7 Hz, 1H), 4.18 – 4.08 (m, 
1H), 3.93 (q, J = 4.9 Hz, 1H), 3.82 – 3.64 (m, 3H), 3.05 (dd, J = 14.2, 3.9 Hz, 1H), 2.90 
(dd, J = 14.0, 3.2 Hz, 1H), 2.82 (t, J = 7.1 Hz, 2H), 2.79 – 2.56 (m, 15H), 2.38 (t, J = 8.6 
Hz, 1H), 2.21 (t, J = 8.5 Hz, 1H), 1.79 – 1.55 (m, 7H), 1.56 – 1.47 (m, 11H), 1.47 – 1.37 
(m, 5H), 1.37 – 1.23 (m, 3H), 1.24 – 1.19 (m, 1H), 1.05 (d, J = 6.3 Hz, 4H), 0.86 (t, J = 6.7 
Hz, 7H), 0.83 – 0.74 (m, 13H); 13C NMR (126 MHz, DMSO-d6) δ 173.4 , 172.1 , 171.7 , 
171.6 , 171.4 , 171.3 , 170.9 , 170.9 , 170.4 , 169.6 , 168.7 , 167.9 , 155.9 , 155.8 , 137.5 , 
130.1 , 130.0 , 129.1 , 128.0 , 126.2 , 118.5 , 114.9 , 114.9 , 66.9 , 57.9 , 56.3 , 55.0 , 54.5 
, 54.3 , 53.6 , 52.5 , 52.2 , 52.1 , 51.2 , 49.7 , 40.7 , 40.3 , 39.3 , 39.1 , 38.8 , 38.7 , 38.7 , 
36.3 , 31.5 , 31.2 , 26.7 , 26.6 , 26.4 , 24.1 , 24.0 , 23.8 , 23.2 , 23.1 , 22.3 , 22.3 , 21.6 , 
21.5 , 19.3 , 14.5 , 11.1; IR (KBr, cm-1) 3285(br), 3080(br), 2960(m), 1676(s), 1634(s), 
1516(m), 1203(m), 1137(m). 
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Peptide SI-9 was constructed by SPPS from 0.20 mmol loaded 2-chloro-chlorotirtyl resin. 
Removal of the peptide from resin was conducted with cocktail C following the general 
cleavage method. The peptide was purified by reverse-phase HPLC (5 - 60% organic over 
15 min) to give 124 mg (51% • 2 TFA salt form) of a white amorphous powder after ly-
ophilization: HRMS (ES) Found m/z 997.4268 [(M+H)+; calcd for C38H69N12O13S3: 
997.4269]; 1H NMR (500 MHz, DMSO-d6) δ 8.8 (d, J = 7.9 Hz, 1H), 8.5 (d, J = 7.4 Hz, 
1H), 8.2 (s, 3H), 8.2 (d, J = 7.6 Hz, 1H), 8.1 (d, J = 7.7 Hz, 1H), 8.1 (d, J = 6.9 Hz, 1H), 
7.9 (d, J = 7.1 Hz, 1H), 7.9 (dd, J = 8.0, 2.4 Hz, 2H), 7.8 (s, 3H), 7.5 (d, J = 26.5 Hz, 2H), 
7.0 (d, J = 30.5 Hz, 2H), 5.1 (s, 1H), 4.6 (q, J = 7.1 Hz, 1H), 4.5 (td, J = 7.5, 5.3 Hz, 1H), 
4.4 (td, J = 7.7, 5.0 Hz, 1H), 4.3 (ddd, J = 13.6, 9.1, 4.8 Hz, 1H), 4.3 (d, J = 7.6 Hz, 1H), 
4.2 – 4.2 (m, 2H), 4.1 (td, J = 8.5, 4.7 Hz, 1H), 3.9 (s, 1H), 3.6 (s, 1H), 3.6 (s, 1H), 2.9 – 
2.7 (m, 7H), 2.6 (dd, J = 15.5, 6.1 Hz, 1H), 2.5 (d, J = 1.8 Hz, 10H), 2.5 – 2.4 (m, 3H), 2.3 
(t, J = 8.6 Hz, 1H), 2.2 (dd, J = 9.1, 6.5 Hz, 2H), 2.0 (s, 3H), 2.0 – 1.9 (m, 3H), 1.9 – 1.8 
(m, 1H), 1.8 – 1.7 (m, 1H), 1.6 (dt, J = 11.3, 5.5 Hz, 2H), 1.6 – 1.5 (m, 2H), 1.5 (t, J = 7.3 
Hz, 2H), 1.3 (q, J = 8.2 Hz, 2H), 1.2 (d, J = 7.1 Hz, 3H), 0.9 (d, J = 6.5 Hz, 3H), 0.8 (d, J 
= 6.5 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 173.5, 173.4, 172.1, 172.0, 171.6, 171.3, 
171.0, 170.3, 169.7, 169.2, 168.5, 61.4, 55.7, 55.0, 54.7, 52.1, 51.8, 51.8, 51.1, 49.9, 48.4, 
40.5, 38.6, 37.0, 31.3, 30.3, 30.3, 29.6, 27.0, 26.6, 26.4, 26.4, 24.1, 23.2, 22.4, 21.5, 17.6, 
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14.7; IR (KBr, cm-1) 3286(br), 3078(w), 2960(w), 1664(s), 1635(s), 1541(m), 1202(m), 
1137(w), 1033(m), 1008(m). 
Peptide SI-10. was constructed by automated SPPS from 0.10 mmol pre-loaded Fmoc-
Cys(Trt)-Wang resin. Removal of the peptide from resin was conducted with cocktail B 
following the general cleavage method. The peptide was purified by reverse-phase HPLC 
(10 - 60% organic over 15 min) to give 38 mg (19% • 3 TFA salt form) of a white amor-
phous powder after lyophilization: MALDI-TOF Found m/z 1639.125 [(M+H)+; calcd for 
C76H107N18O19S2: 1639.740]; 
1H NMR (500 MHz, DMSO-d6) δ 10.79 (s, 1H), 8.67 (t, J = 
5.8 Hz, 1H), 8.28 – 8.01 (m, 8H), 8.01 – 7.87 (m, 4H), 7.84 – 7.64 (m, 7H), 7.61 (d, J = 
7.9 Hz, 1H), 7.47 (s, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.28 – 7.13 (m, 13H), 7.13 – 7.08 (m, 
5H), 7.08 – 7.01 (m, 2H), 6.98 (t, J = 7.4 Hz, 1H), 6.60 (s, 1H), 5.17 – 5.07 (m, 1H), 4.90 
(d, J = 5.0 Hz, 1H), 4.71 – 4.62 (m, 1H), 4.57 (q, J = 7.4 Hz, 1H), 4.51 (q, J = 6.8 Hz, 2H), 
4.48 – 4.41 (m, 3H), 4.41 – 4.30 (m, 5H), 4.25 – 4.15 (m, 2H), 4.05 – 3.93 (m, 3H), 3.94 – 
3.86 (m, 2H), 3.82 (dd, J = 16.8, 5.6 Hz, 1H), 3.72 – 3.54 (m, 4H), 3.50 (s, 1H), 3.18 – 3.11 
(m, 2H), 3.11 – 3.05 (m, 2H), 3.03 – 2.93 (m, 3H), 2.93 – 2.75 (m, 7H), 2.75 – 2.62 (m, 
7H), 2.45 – 2.39 (m, 1H), 2.36 (dd, J = 15.5, 6.3 Hz, 1H), 1.71 – 1.56 (m, 3H), 1.56 – 1.39 
(m, 8H), 1.35 (d, J = 7.0 Hz, 3H), 1.32 – 1.16 (m, 5H), 1.14 (d, J = 6.8 Hz, 1H), 1.04 (d, J 
= 6.3 Hz, 3H), 0.99 (d, J = 6.2 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 171.8, 171.4, 
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171.4, 171.2, 171.1, 171.0, 170.9, 170.7, 170.5, 169.9, 169.8, 169.7, 169.7, 169.7, 168.4, 
137.8, 137.6, 137.6, 136.1, 129.3, 129.3, 129.1, 128.1, 128.0, 128.0, 127.4, 126.2, 126.2, 
123.7, 120.9, 118.3, 109.9, 72.5, 70.6, 70.5, 69.8, 66.8, 66.5, 63.1, 61.8, 61.6, 57.9, 57.9, 
57.8, 57.8, 55.0, 54.6, 54.1, 53.9, 53.7, 53.4, 52.4, 52.3, 49.6, 48.2, 41.8, 37.4, 37.2, 37.1, 
31.3, 31.2, 27.7, 26.7, 26.7, 26.6, 25.6, 22.3, 22.2, 19.4, 19.3, 19.3, 17.3; IR (KBr, cm-1) 
3399(br), 3298(br), 3063(w), 2929(w), 1663(s), 1553(m), 1202(w), 1134(w), 1032(w), 
1008(w). 
Peptide SI-11. was constructed by automated SPPS from 0.10 mmol loaded Rink amide 
resin. Removal of the peptide from resin was conducted with cocktail B following the gen-
eral cleavage method. The peptide was purified by reverse-phase HPLC (10 - 60% organic 
over 20 min) to give 39.6 mg (11% • 4 TFA salt form) of a white amorphous powder after 
lyophilization: MALDI-TOF Found m/z 3600.001 [(M+H)+; calcd for C156H231N45O48S3: 
3599.625];  IR (KBr, cm-1) 3306(br), 2933(w), 1655(s), 1541(m), 1202(m). 
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General Phase-Transfer Protocol for Tetrazine Insertion 
 
A round bottom flask, was charged with unprotected peptide 1 (1 - 1000 µmol) then sealed 
with a septum and purged with argon. Next, a degassed solution of 50mM (pH ~5) mono-
sodium phosphate was added (1 -2 mM concentration of peptide in solution) followed by 
a solution of dichlorotetrazine (3 equiv) in CHCl3 (equal volume to peptide). The two-
phases were stirred vigorously for 1 minute. The mixture was divide between Falcon tubes 
then transferred to a benchtop centrifuge and further separated at 2500 RPM for 1 minute. 
The aqueous phase, now orange in color, was collected and each organic layer was ex-
tracted with an additional portion of water then transferred to a benchtop centrifuge and 
separated again at 2500 RPM for 1 minute. All of the aqueous fractions were combined 
and lyophilized. The crude mixture was then purified by reverse-phase high-pressure liquid 
chromatography (HPLC) to yield an orange powder after lyophilization. 
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Conditions for the above reaction are different from the general phase-transfer protocol and 
employ only 1.1 equivalents of dichlorotetrazine to illustrate the colorimetric transfer of 
tetrazine into the peptide.  
 
Peptide 33.  Peptide 1a (5.7 mg, 10 µmol) was subjected to the general phase-transfer 
protocol to construct 33. The crude reaction mixture was purified by reverse-phase HPLC 
(gradient 5-15% organic over 5 min) to give (5.1 mg, 78%) of an orange powder after 
lyophilization. HRMS (ES) Found m/z 647.2028 [(M+H)+; calcd for C22H35N10O9S2: 
647.2030]; 1H NMR (500 MHz, D2O) δ ppm 1.36 (quin, J=7.80 Hz, 2 H) 1.58 - 1.66 (m, 3 
aqueous buffer
(peptide)
chloroform
(dichlorotetrazine)
aqueous buffer
(S,S-tetrazine peptide)
chloroform
(dichlorotetrazine)
< 1minute
on vortex
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H) 1.68 (q, J=7.90 Hz, 2 H) 1.79 (ddd, J=13.90, 8.30, 5.50 Hz, 1 H) 1.78 (ddd, J=13.25, 
8.10, 5.30 Hz, 1 H) 2.07 (q, J=7.34 Hz, 2 H) 2.39 (dd, J=7.30, 5.10 Hz, 1 H) 2.39 (dd, 
J=9.80, 7.40 Hz, 1 H) 2.93 (t, J=7.48 Hz, 9 H) 3.50 (dd, J=15.60, 4.06 Hz, 3 H) 3.54 (dd, 
J=18.20, 6.20 Hz, 1 H) 3.57 (dd, J=11.30, 7.70 Hz, 1 H) 4.10 (t, J=6.52 Hz, 1 H) 4.14 (dd, 
J=8.44, 5.24 Hz, 1 H) 4.20 (dd, J=7.10, 6.40 Hz, 1 H) 4.53 (dd, J=15.39, 2.99 Hz, 1 H) 
4.56 (dd, J=15.60, 4.92 Hz, 1 H) 4.80 (t, J=3.42 Hz, 1 H) 4.99 (dd, J=4.90, 1.90 Hz, 1 H); 
13C NMR (126 MHz, Deuterium Oxide) δ 178.6, 178.1, 171.7, 170.6, 170.4, 169.9, 169.1, 
169.1, 61.8, 55.0, 53.9, 52.4, 52.2, 51.5, 39.1, 31.4, 31.1, 30.7, 30.2, 26.7, 26.2, 22.1; IR 
(KBr, cm-1) 3430(br), 3291(br), 3074(br), 2945(br), 1658(s), 1525(m), 1197(s), 1139(m); 
UV-vis λMax 278 nm, 419 nm, 507 nm. 
 
(Large Scale) Peptide 33.  Peptide 32 (570 mg, 1000 µmol) was subjected to the general 
phase-transfer protocol to construct 33. The crude reaction mixture was purified by reverse-
phase HPLC (gradient 5-15% organic over 5 min) to give (465 mg, 72 %) of an orange 
powder after lyophilization. Spectral data was identical to compound 33.  
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UV-Vis Spectrum of Peptide 33 [73 μM] in pH 7.8 buffer 
 
Zoom Region 300 – 600 nm: UV-Vis Spectrum of Peptide 33 [73 μM] in pH 7.8 buffer 
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Table of Stabilty Data for the S,S-Tetrazine Peptide 33 
 
Buffer Stability 
100 mM phosphate buffer; pH 5 stable for > 1 week 
100 mM phosphate buffer; pH 7 stable for > 1 week 
100 mM phosphate buffer; pH 8 stable for > 1 week 
100 mM phosphate buffer; pH 10 slowly decomposes half-life ≤ 4 days 
100 mM acetate buffer, pH 5 stable for > 1 week 
100 mM Tris buffer, pH 7 stable for > 1 week 
100 mM Tris buffer pH 9 slowly decomposes half-life ≥ 1 week 
100 mM ammonium bicarbonate stable for > 1 week 
citric acid buffer, pH 3 stable for > 1 week 
6 M Guanidine HCl, pH 7 PBS stable for > 1 week 
8 M Urea, pH 7 PBS stable for > 1 week 
Storage Conditions Storage Period 
ambient temperature stable for months as a lyophilized powder 
elevated temperature stable after reflux in water (100ºC) for 24 hours 
freeze-thaw cycles stable for 5 cycles of freeze-thaw in buffer 
light exposure stable for >1 week in buffer under fluorescent lights, sta-
ble for months as a lyophilized powder 
refrigerated temperature stable for > 1 year when stored as a lyophilized powder 
in a refrigerator at 10ºC 
Organic solvents/Reagents Stability 
Methanol stable for  > 1 week 
dimethyl sulfoxide stable for  > 1 week 
acetonitrile/water (4:1) stable for  > 1 week 
glycerol/water (1:1) stable for  > 1 week 
trifluoroethanol stable for  > 1 week 
trifluoroacetic acid stable for  > 2 days 
dimethyl sulfoxide/trimethylamine (9:1) decomposes 
1 mM cysteine in 100 mM Tris buffer, pH 7 turns colorless, mass of 33 increases by 2 
1 mM TCEP in 100 mM Tris buffer, pH 7 turns colorless, mass of 33 increases by 2 
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Peptide 36.  Peptide SI-4 (14.1 mg, 23µmol) was subjected to the general phase-transfer 
protocol to construct 36. The crude reaction mixture was purified by reverse-phase HPLC 
(gradient 5-30% organic over 10 min) to give (10.5 mg, 67%) of an orange powder after 
lyophilization.: HRMS (ES) Found m/z 684.2341 [(M+H)+; calcd for C25H38N11O8S2: 
684.2346]; 1H NMR (500MHz ,DMSO-d6) δ = 8.71 (d, J = 6.8 Hz, 1 H), 8.46 (d, J = 4.5 
Hz, 1 H), 8.00 (d, J = 7.7 Hz, 1 H), 7.91 (d, J = 9.6 Hz, 1 H), 7.43 (s, 1 H), 7.15 (br. s., 3 
H), 7.04 (s, 1 H), 4.77 (dd, J = 3.4, 6.8 Hz, 1 H), 4.74 (dd, J = 2.6, 15.8 Hz, 1 H), 4.69 (dd, 
J = 1.9, 9.0 Hz, 1 H), 4.67 (dd, J = 1.9, 9.6 Hz, 1 H), 4.42 - 4.34 (m, 1 H), 4.20 (quin, J = 
7.2 Hz, 1 H), 4.06 (dd, J = 11.2, 14.6 Hz, 1 H), 3.77 (dd, J = 5.9, 7.9 Hz, 1 H), 3.66 (d, J = 
5.1 Hz, 1 H), 3.54 - 3.47 (m, 2 H), 3.44 (dd, J = 2.6, 15.4 Hz, 1 H), 3.42 (dd, J = 2.8, 10.0 
Hz, 1 H), 2.37 (dd, J = 2.4, 17.1 Hz, 1 H), 2.19 (dd, J = 10.5, 17.3 Hz, 1 H), 2.06 (sxt, J = 
6.8 Hz, 1 H), 1.99 - 1.88 (m, 2 H), 1.77 (quind, J = 6.6, 12.0 Hz, 1 H), 1.71 - 1.62 (m, 1 
H), 1.24 (d, J = 7.1 Hz, 3 H), 0.93 (d, J = 7.1 Hz, 3 H), 0.91 (d, J = 6.8 Hz, 3 H); 13C NMR 
(126 MHz, DMSO) δ 173.8, 171.4, 171.1, 171.1, 171.1, 168.7, 168.4, 167.4, 158.3, 59.6, 
57.6, 54.3, 51.2, 48.4, 48.1, 46.4, 34.6, 32.0, 31.0, 30.1, 28.6, 25.0, 18.6, 18.5, 17.6; IR 
(KBr, cm-1) 3285(br), 3069(br), 1671(s), 1639(s), 1523(m), 1406(w), 1240(m), 1201(m), 
1137(m). 
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Peptide 37.  Peptide SI-5 (15.3 mg, 21µmol) was subjected to the general phase-transfer 
protocol to construct 37. The crude reaction mixture was purified by reverse-phase HPLC 
(gradient 5-40% organic over 15 min) to give (12.9 mg, 76%) of an orange powder after 
lyophilization: HRMS (ES) Found m/z 820.2981 [(M+H)+; calcd for C32H46N13O9S2: 
820.2983]; 1H NMR (500MHz, DMSO-d6) δ = 9.36 (s, 1 H), 9.16 (d, J = 7.3 Hz, 1 H), 8.72 
(dd, J = 4.1, 7.0 Hz, 1 H), 8.22 (d, J = 7.3 Hz, 1 H), 8.19 - 8.15 (m, 3 H), 7.88 (d, J = 8.1 
Hz, 1 H), 7.84 (d, J = 8.3 Hz, 1 H), 7.73 (t, J = 5.7 Hz, 1 H), 7.24 (s, 1 H), 7.05 (br. s., 1 
H), 7.03 (d, J = 8.5 Hz, 2 H), 6.96 (br. s., 1 H), 6.69 (d, J = 8.3 Hz, 2 H), 6.51 (s, 1 H), 4.81 
- 4.72 (m, 2 H), 4.28 (quin, J = 7.2 Hz, 1 H), 4.21 (dt, J = 6.0, 8.5 Hz, 1 H), 4.03 (t, J = 6.0 
Hz, 1 H), 4.00 (dd, J = 7.5, 16.2 Hz, 1 H), 3.80 (dd, J = 4.1, 10.3 Hz, 1 H), 3.77 (dd, J = 
6.0, 16.5 Hz, 1 H), 3.71 - 3.55 (m, 4 H), 3.49 (dd, J = 3.8, 16.0 Hz, 1 H), 3.02 (dd, J = 5.6, 
14.3 Hz, 1 H), 2.85 (dd, J = 7.5, 13.9 Hz, 1 H), 1.65 - 1.55 (m, 1 H), 1.51 - 1.42 (m, 2 H), 
1.25 (d, J = 7.1 Hz, 3 H), 0.88 (d, J = 6.6 Hz, 3 H), 0.84 (d, J = 6.4 Hz, 3 H); 13C NMR 
(126MHz ,DMSO-d6) δ = 174.0, 172.2, 171.6, 171.0, 169.2, 169.1, 169.0, 169.0, 168.8, 
168.2, 158.1, 156.5, 130.5, 124.6, 115.3, 53.6, 52.6, 52.1, 50.9, 48.6, 42.5, 42.2, 42.1, 40.9, 
36.0, 32.0, 31.3, 24.2, 23.0, 21.6, 17.8; IR (KBr, cm-1) 3293(br), 2928(w), 1670(s), 
1517(m), 1238(m). 
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Peptide 38.  Peptide SI-6 (16.0 mg, 21 µmol) was subjected to the general phase-transfer 
protocol to construct 38. The crude reaction mixture was purified by reverse-phase HPLC 
(gradient 5-40% organic over 15 min) to give (11.2 mg, 64%) of an orange powder after 
lyophilization: HRMS (ES) Found m/z 848.3286 [(M+H)+; calcd for C34H50N13O9S2: 
848.3296]; 1H NMR (500MHz ,DMSO-d6) δ = 9.36 (br. s., 1 H), 8.76 (d, J = 7.5 Hz, 1 H), 
8.31 (t, J = 5.4 Hz, 1 H), 8.21 (d, J = 6.3 Hz, 1 H), 8.16 - 8.06 (m, 3 H), 8.02 (t, J = 5.9 Hz, 
1 H), 7.96 (d, J = 8.1 Hz, 1 H), 7.77 (d, J = 7.7 Hz, 1 H), 7.23 (br. s., 1 H), 7.04 (d, J = 7.1 
Hz, 2 H), 6.96 (br. s., 1 H), 6.70 (d, J = 7.1 Hz, 2 H), 4.59 (t, J = 9.0 Hz, 1 H), 4.45 (dd, J 
= 6.9, 15.0 Hz, 1 H), 4.26 (ddd, J = 6.5, 7.3, 14.9 Hz, 1 H), 4.20 (dd, J = 7.5, 15.9 Hz, 1 
H), 4.02 (br. s., 1 H), 3.90 (dd, J = 5.9, 16.1 Hz, 1 H), 3.77 (dd, J = 5.2, 16.4 Hz, 1 H), 3.74 
(dd, J = 4.8, 14.9 Hz, 1 H), 3.69 - 3.53 (m, 4 H), 3.41 - 3.33 (m, 2 H), 3.24 (quin, J = 7.4 
Hz, 2 H), 2.99 (dd, J = 5.0, 13.7 Hz, 1 H), 2.83 (dd, J = 7.5, 14.1 Hz, 1 H), 2.30 (d, J = 7.7 
Hz, 1 H), 2.08 (ddd, J = 5.4, 8.7, 14.3 Hz, 1 H), 2.04 - 1.91 (m, 2 H), 1.59 (dt, J = 6.4, 13.0 
Hz, 1 H), 1.51 - 1.38 (m, 1 H), 1.23 (d, J = 7.1 Hz, 3 H), 0.87 (d, J = 5.4 Hz, 3 H), 0.83 (d, 
J = 5.7 Hz, 3 H); 13C NMR (126MHz ,DMSO-d6) δ = 174.1, 171.8, 171.7, 171.7, 170.8, 
170.5, 169.2, 169.1, 168.8, 168.3, 156.6, 130.5, 124.8, 115.4, 53.7, 51.4, 51.2, 50.8, 48.5, 
42.6, 42.3, 42.1, 41.0, 36.1, 31.5, 31.2, 26.4, 26.2, 24.2, 23.1, 21.6, 17.7; IR (KBr, cm-1) 
3290(br), 2927(w), 1672(s), 1516(m), 1240(m).  
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Peptide 39.  Peptide SI-7 (11.0 mg, 11.8 µmol) was subjected to the general phase-transfer 
protocol to construct 39. The crude reaction mixture was purified by reverse-phase HPLC 
(gradient 10-60% organic over 15 min) to give 6.2 mg (52%) of an orange powder after 
lyophilization: HRMS (ES) Found m/z 1011.4095 [(M+H)+; calcd for C47H59N14O8S2: 
1011.4082]; 1H NMR (500 MHz, DMSO-d6) δ 10.87 (s, 1H), 9.07 (d, J = 8.3 Hz, 1H), 8.57 
(d, J = 8.2 Hz, 1H), 8.36 (d, J = 8.6 Hz, 1H), 8.30 (d, J = 8.6 Hz, 1H), 8.23 (d, J = 8.4 Hz, 
1H), 8.14 (s, 3H), 7.73 (s, 3H), 7.66 (d, J = 7.9 Hz, 1H), 7.50 (d, J = 8.1 Hz, 1H), 7.38 (d, 
J = 30.6 Hz, 2H), 7.31 (d, J = 8.0 Hz, 1H), 7.30 – 7.28 (m, 4H), 7.28 – 7.21 (m, 2H), 7.17 
(d, J = 2.4 Hz, 1H), 7.12 – 6.97 (m, 5H), 6.88 (d, J = 6.8 Hz, 2H), 6.59 (s, 1H), 4.97 (d, J 
= 4.8 Hz, 1H), 4.84 (td, J = 8.8, 4.5 Hz, 1H), 4.70 (dd, J = 8.3, 3.4 Hz, 1H), 4.68 – 4.64 (m, 
1H), 4.57 (ddd, J = 14.2, 8.6, 5.8 Hz, 1H), 4.28 (dt, J = 14.3, 8.6, 6.1 Hz, 2H), 4.20 (dd, J 
= 8.2, 4.5 Hz, 1H), 4.15 – 4.07 (m, 1H), 3.86 (q, J = 5.3 Hz, 1H), 3.67 – 3.53 (m, 2H), 3.45 
(dd, J = 14.0, 8.2 Hz, 1H), 3.09 (dt, J = 13.9, 5.3 Hz, 3H), 2.88 (ddd, J = 19.7, 14.2, 9.2 
Hz, 2H), 2.75 – 2.66 (m, 5H), 2.63 (dd, J = 13.4, 4.8 Hz, 1H), 1.61 (dq, J = 17.3, 5.4 Hz, 
1H), 1.54 – 1.38 (m, 3H), 1.27 – 1.07 (m, 3H), 0.96 (d, J = 6.3 Hz, 3H); 13C NMR (126 
MHz, DMSO-d6) δ 171.6, 171.4, 171.3, 171.0, 170.0, 169.0, 168.5, 168.4, 157.8, 137.2, 
136.2, 134.8, 129.6, 129.3, 128.6, 127.9, 127.2, 127.1, 126.2, 124.1, 121.0, 118.6, 118.3, 
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111.4, 109.8, 66.9, 57.4, 53.6, 53.5, 53.4, 52.9, 51.4, 50.4, 38.7, 37.9, 37.3, 33.8, 32.0, 30.7, 
28.7, 26.6, 22.1, 19.5. 
 
Peptide 40.  Peptide SI-8 (17.0 mg, 10µmol) was subjected to the general phase-transfer 
protocol to construct 40. The crude reaction mixture was purified by reverse-phase HPLC 
[eluent water/MeCN/AcOH (85:10:5) and MeCN (organic) buffered with 0.1%TFA] (gra-
dient 0-60% organic over 20 min) to give (11.8 mg, 67%) of an orange powder after ly-
ophilization: MALDI-TOF Found m/z 1793.153 [(M+Na)+; calcd for C81H122N22NaO19S2: 
1793.860]; 1H NMR (500 MHz, DMSO-d6) δ 8.93 (s, 1H), 8.63 (d, J = 7.2 Hz, 1H), 8.41 
(d, J = 8.3 Hz, 1H), 8.27 (d, J = 7.6 Hz, 1H), 8.23 – 8.12 (m, 6H), 8.12 – 8.05 (m, 1H), 
8.01 (s, 7H), 7.95 (s, 3H), 7.89 (d, J = 8.0 Hz, 2H), 7.43 (s, 1H), 7.29 – 7.23 (m, 1H), 7.22 
(s, 1H), 7.21 (s, 2H), 7.18 – 7.12 (m, 1H), 7.10 (s, 1H), 7.04 (d, J = 8.3 Hz, 2H), 6.97 (d, J 
= 8.3 Hz, 2H), 6.65 (d, J = 8.0 Hz, 2H), 6.62 (d, J = 8.2 Hz, 2H), 4.84 (q, J = 6.5 Hz, 1H), 
4.73 – 4.63 (m, 2H), 4.59 (dd, J = 13.9, 5.9 Hz, 1H), 4.42 (dq, J = 15.0, 7.6 Hz, 2H), 4.34 
– 4.22 (m, 3H), 4.22 – 4.09 (m, 3H), 3.92 (dd, J = 12.5, 6.8 Hz, 3H), 3.81 – 3.68 (m, 3H), 
3.02 (dd, J = 14.2, 4.3 Hz, 1H), 2.89 (dd, J = 34.1, 11.3 Hz, 3H), 2.85 – 2.79 (m, 1H), 2.74 
(h, J = 6.1 Hz, 8H), 2.66 (dd, J = 16.2, 4.8 Hz, 2H), 1.73 – 1.61 (m, 2H), 1.59 – 1.51 (m, 
10H), 1.50 – 1.42 (m, 3H), 1.32 (dt, J = 15.7, 7.9 Hz, 9H), 1.22 (d, J = 6.9 Hz, 1H), 1.05 
(d, J = 6.1 Hz, 4H), 0.88 (d, J = 6.5 Hz, 3H), 0.85 (d, J = 6.3 Hz, 3H), 0.83 (d, J = 6.5 Hz, 
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3H), 0.81 (d, J = 4.0 Hz, 3H), 0.80 (d, J = 3.7 Hz, 4H), 0.78 (d, 3H), 0.75 (d, J = 6.4 Hz, 
3H); 13C NMR (126 MHz, DMSO-d6) δ 173.5, 172.1, 171.7, 171.6, 171.4, 171.4, 171.1, 
170.9, 170.8, 170.7, 169.2, 169.2, 169.0, 168.7, 167.8, 155.9, 155.8, 137.4, 130.2, 129.2, 
128.0, 127.7, 127.5, 126.3, 66.9, 65.8, 58.3, 56.3, 54.5, 54.4 , 53.5 , 52.8 , 52.4 , 52.2 , 51.1 
, 50.8 , 49.6 , 42.0 , 38.5 , 37.4 , 36.7 , 36.3 , 36.2 , 31.4 , 30.8, 26.5, 26.5, 26.5, 24.0, 23.9, 
23.5, 23.1, 22.3, 22.2, 21.8, 21.5, 21.2, 19.4, 14.5, 11.2; IR (KBr, cm-1) 3412(br), 2963(w), 
1668(s), 1517(m), 1238(w), 1203(m), 1134(m), 1033(w), 1009(w). 
 
Peptide 41.  Peptide SI-9 (10.0 mg, 10 µmol) was subjected to the general phase-transfer 
protocol to construct 41. The crude reaction mixture was purified by reverse-phase HPLC 
[elutant water/MeCN/AcOH (85:10:5) and MeCN (organic) buffered with 0.1%TFA] (gra-
dient 0-60% organic over 15 min) to give (4.7 mg, 44 %) of an orange powder after lyoph-
ilization: HRMS (ES) Found m/z 1075.4239 [(M+H)+; calcd for C34H50N13O9S2: 
1075.4236]1H NMR (500 MHz, DMSO-d6) δ 9.19 (d, J = 8.1 Hz, 1H), 8.47 (d, J = 7.3 Hz, 
1H), 8.41 – 8.28 (m, 5H), 8.22 (d, J = 8.1 Hz, 1H), 8.07 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 
5.2 Hz, 1H), 7.99 – 7.89 (m, 3H), 7.66 (s, 2H), 7.59 – 7.48 (m, 2H), 7.08 (s, 1H), 6.98 (s, 
1H), 4.82 (ddd, J = 13.6, 8.2, 5.0 Hz, 1H), 4.65 (dd, J = 14.7, 6.9 Hz, 1H), 4.53 (dd, J = 
13.7, 6.2 Hz, 1H), 4.28 – 4.05 (m, 6H), 3.86 (dd, J = 11.3, 5.8 Hz, 1H), 3.79 – 3.69 (m, 
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3H), 3.64 (dd, J = 14.0, 6.9 Hz, 1H), 2.73 (q, J = 6.8 Hz, 2H), 2.67 (dd, J = 15.6, 6.5 Hz, 
1H), 2.58 (dd, J = 15.3, 6.1 Hz, 1H), 2.42 – 2.34 (m, 1H), 2.23 (dd, J = 9.2, 6.7 Hz, 2H), 
2.01 (s, 4H), 1.94 (q, J = 7.4 Hz, 2H), 1.86 – 1.77 (m, 1H), 1.77 – 1.68 (m, 1H), 1.65 – 1.46 
(m, 5H), 1.44 – 1.30 (m, 5H), 1.16 (d, J = 7.1 Hz, 3H), 0.88 (d, J = 6.5 Hz, 3H), 0.83 (d, J 
= 6.5 Hz, 4H); 13C NMR (126 MHz, DMSO-d6) δ 173.5, 173.1, 172.2, 172.1, 172.0, 171.7, 
171.3, 170.9, 170.2, 169.4, 168.8, 168.7, 61.1, 56.0, 52.1, 51.8, 51.8, 51.6, 51.2, 50.2, 48.6, 
38.5, 36.8, 32.3, 30.9, 30.4, 30.4, 30.2, 29.9, 27.0, 26.5, 24.2, 23.2, 22.2, 21.5, 17.8, 14.6; 
IR (KBr, cm-1) 3413(br), 2923(m), 1655(s), 1541(m), 1236(m). 
 
Peptide 42.  Peptide SI-10 (8.3 mg, 5.1 µmol) was subjected to the general phase-transfer 
protocol to construct 42. The crude reaction mixture was purified by reverse-phase HPLC 
(gradient 10-60% organic over 15 min) to give (5.5 mg, 63%) of an orange powder after 
lyophilization: MALDI-TOF Found m/z 1717.968 [(M+H)+; calcd for C78H105N22O19S2: 
1717.736]. 1H NMR (500 MHz, DMSO-d6) δ 10.79 (s, 1H), 8.66 (t, J = 4.9 Hz, 2H), 8.50 
(d, J = 6.4 Hz, 2H), 8.43 – 8.37 (m, 1H), 8.33 – 8.26 (m, 1H), 8.20 – 8.16 (m, 5H), 8.12 – 
8.06 (m, 1H), 8.05 – 8.01 (m, 5H), 7.93 (d, J = 5.2 Hz, 1H), 7.88 – 7.83 (m, 13H), 7.79 – 
7.72 (m, 2H), 7.70 – 7.65 (m, 3H), 7.58 (d, J = 7.5 Hz, 2H), 7.37 – 7.27 (m, 1H), 7.25 – 
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7.04 (m, 22H), 7.04 – 6.93 (m, 2H), 5.44 – 5.40 (m, 1H), 5.26 – 5.19 (m, 1H), 5.16 – 5.10 
(m, 1H), 4.96 – 4.92 (m, 1H), 4.86 – 4.79 (m, 1H), 4.79 – 4.71 (m, 1H), 4.62 – 4.52 (m, 
2H), 4.47 – 4.41 (m, 1H), 4.34 – 4.29 (m, 6H), 4.26 – 4.22 (m, 2H), 4.15 – 4.08 (m, 1H), 
3.99 – 3.95 (m, 1H), 3.92 – 3.86 (m, 2H), 3.84 (d, J = 5.8 Hz, 1H), 3.81 – 3.73 (m, 1H), 
3.62 – 3.58 (m, 3H), 1.69 – 1.65 (m, 3H), 1.57 – 1.39 (m, 3H), 1.36 (t, J = 7.2 Hz, 3H), 
1.23 (d, J = 7.0 Hz, 2H), 1.05 – 0.99 (m, 5H), 0.96 (t, J = 6.2 Hz, 3H); 13C NMR (126 MHz, 
DMSO) δ 176.4, 171.9, 171.7, 171.6, 171.4, 171.2, 171.0, 171.0, 170.9, 170.9, 170.8, 
170.1, 169.9, 169.7, 169.4, 168.6, 168.5, 137.8, 137.7, 137.6, 137.5, 136.2, 136.1, 129.2, 
129.2, 129.1, 128.9, 128.9, 128.1, 128.1, 127.3, 127.1, 126.3, 123.7, 72.5, 69.8, 67.0, 66.9, 
66.5, 65.8, 63.1, 61.8, 61.5, 57.8, 55.2, 55.1, 54.8, 54.0, 53.7, 53.5, 52.7, 52.4, 51.1, 49.6, 
48.2, 43.2, 41.8, 38.7, 37.5, 37.2, 37.0, 36.6, 26.7, 26.6, 26.5, 26.5, 22.5, 22.2, 20.5, 19.4, 
19.0, 17.3; IR (KBr, cm-1) 3421(br), 2925(m), 1654(s), 1508(m), 1117(m), 1032(s), 
1008(s). 
 
Peptide 43.  Peptide SI-11 (7.2 mg, 2 µmol) was subjected to the general phase-transfer 
protocol with 6M guanidine hydrochloride additive to construct 43, the salts were removed 
by dialysis and the crude reaction mixture was purified by reverse-phase HPLC (10 - 60% 
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organic over 20 min) to give (1.5 mg, 21%) of an orange powder after lyophilization. 
MALDI-TOF Found m/z 3677.277 [(M+H)+; calcd for C158H230N49O48S3: 3677.622]. 
General Procedure for Unstapling S,S-Tetrazine Peptides Photochemically 
 
A 10 mL glass vial was charged with a solution of tetrazine stapled peptide in MeOH (1-2 
mM). The contents were capped with a septum and sparged with oxygen gas for 15 
minutes. The solution was then irradiated in a Rayonet® photoreactor equipped with four 
(7 watt) UV-B lamps (λMax = 312 nm) until the solution turned colorless. The MeOH was 
evaporated in vacuo, then redissolved in water and lyophilized to yield a white amorphous 
powder. 
Colormetric Change that Occurs After Irradiation in a Rayonet® Photoreactor 
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Peptide 34.  Peptide 33 (10.0 mg, 15 µmol) was subjected to the general photochemical 
unstapling protocol to yield 9.4 mg (98%). HRMS (ES) Found m/z 619.1961 [(M+H)+; 
calcd for C22H35N8O9S2: 619.1963]; 
1H NMR (500 MHz, Deuterium Oxide) δ 4.96 (dd, J 
= 7.4, 5.4 Hz, 1H), 4.89 (dd, J = 7.9, 5.0 Hz, 1H), 4.61 (t, J = 5.6 Hz, 1H), 4.36 (dd, J = 
8.6, 5.1 Hz, 1H), 4.22 (t, J = 6.4 Hz, 1H), 3.93 (d, J = 5.7 Hz, 2H), 3.62 (ddd, J = 14.2, 5.2, 
2.2 Hz, 2H), 3.45 (ddd, J = 14.2, 8.8, 7.7 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 2.59 (t, J = 7.4 
Hz, 2H), 2.26 (q, J = 7.1 Hz, 2H), 1.93 (ddd, J = 13.5, 8.3, 5.1 Hz, 1H), 1.80 (td, J = 14.8, 
14.2, 8.1 Hz, 1H), 1.72 (pd, J = 7.2, 2.2 Hz, 2H), 1.47 (p, J = 7.4, 6.8 Hz, 2H); 13C NMR 
(126 MHz, D2O) δ 177.7, 177.1, 172.8, 171.3, 171.1, 170.9, 115.4, 115.3, 62.5, 57.0, 54.6, 
54.6, 54.5, 53.7, 40.6, 35.7, 35.6, 31.6, 30.5, 27.7, 27.3, 23.5; IR (KBr, cm-1) 3425(br), 
3286(br), 3077(br), 2950(br), 2159(w), 1682(s), 1628(s), 1535(m), 1429(m), 1207(s), 
1132(s). 
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Photochemical Unstapling with UV-A Lamps (λMax = 365 nm) 
 
Peptide 34.  Peptide 33 (15.0 mg, 23 µmol) was dissolved in MeOH (25 mL) and trans-
ferred to a thin-walled pyrex tube. The contents were then irradiated in a Rayonet photore-
actor with twelve (7 watt) UV-A lamps (λMax= 365 nm) for 24 hours, during which time 
the solution turned from red to colorless. The solvent was evaporated then redissolved in 
water and lyophilized to yield 13.8 mg (96%) of a white amorphous powder. Spectral data 
was identical to 34 photolyzed with UV-B lamps. 
 
Peptide 44.  Peptide 36 (1.5 mg, 2.2 µmol) was subjected to the general photochemical 
unstapling protocol to yield 1.4 mg (96%): HRMS (ES) Found m/z 656.2283 [(M+H)+; 
calcd for C25H38N9O8S2: 656.2285]; 
1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J = 7.7 Hz, 
1H), 8.84 (d, J = 7.9 Hz, 1H), 8.08 (d, J = 5.6 Hz, 3H), 7.98 (d, J = 8.0 Hz, 1H), 7.76 (d, J 
= 7.5 Hz, 1H), 7.14 (s, 1H), 7.02 (s, 1H), 4.85 (q, J = 7.1 Hz, 1H), 4.68 (q, J = 7.7 Hz, 1H), 
4.51 (td, J = 8.6, 4.4 Hz, 1H), 4.29 (dd, J = 8.6, 3.6 Hz, 1H), 4.14 (p, J = 7.3 Hz, 1H), 3.67 
101 
 
(dt, J = 10.8, 5.8 Hz, 4H), 3.55 (dd, J = 13.5, 4.6 Hz, 2H), 3.45 (dd, J = 13.5, 5.4 Hz, 1H), 
3.27 (dd, J = 13.3, 9.2 Hz, 1H), 3.20 (dd, J = 13.4, 8.1 Hz, 1H), 2.81 (dd, J = 16.9, 6.6 Hz, 
1H), 2.09 (dt, J = 9.2, 4.5 Hz, 2H), 1.95 (tq, J = 10.2, 5.9, 5.3 Hz, 2H), 1.89 (dd, J = 11.3, 
5.0 Hz, 1H), 1.24 (d, J = 7.0 Hz, 3H), 0.93 (dd, J = 12.7, 6.9 Hz, 6H); 13C NMR (126 MHz, 
DMSO-d6) δ 173.6, 172.0, 171.7, 169.2, 168.0, 167.8, 167.6, 113.0, 112.4, 60.2, 57.2, 52.8, 
52.1, 48.4, 47.7, 46.9, 35.7, 34.9, 34.9, 29.8, 28.8, 24.2, 18.2, 17.8, 17.3; IR (KBr, cm-1) 
3323(br), 3067(m), 2974(m), 2160(w), 1669(s), 1525(m), 1202(m).  
 
Peptide 45.  Peptide 37 (2.8 mg, 3.4 µmol) was subjected to the general photochemical 
unstapling protocol to yield 2.6 mg (97%): HRMS Found (ES) m/z 792.2917 [(M+H)+; 
calcd for C32H46N11O9S2: 792.2921]; 
1H NMR (500 MHz, DMSO-d6) δ 9.34 (s, 1H), 9.06 
(d, J = 8.0 Hz, 1H), 8.52 (t, J = 5.7 Hz, 1H), 8.39 (d, J = 8.2 Hz, 1H), 8.33 (d, J = 7.2 Hz, 
1H), 8.19 (dt, J = 11.2, 5.8 Hz, 2H), 8.08 (s, 3H), 7.77 (d, J = 8.4 Hz, 1H), 7.23 (s, 1H), 
7.05 (d, J = 8.4 Hz, 2H), 6.96 (s, 1H), 6.71 (d, J = 8.4 Hz, 2H), 4.82 – 4.70 (m, 1H), 4.66 
(td, J = 8.3, 4.7 Hz, 1H), 4.26 – 4.16 (m, 2H), 3.99 (d, J = 8.0 Hz, 1H), 3.89 – 3.71 (m, 
6H), 3.67 – 3.58 (m, 1H), 3.49 (td, J = 13.5, 4.9 Hz, 2H), 3.27 (dd, J = 13.5, 7.8 Hz, 1H), 
3.22 – 3.17 (m, 1H), 3.04 (dd, J = 14.3, 5.0 Hz, 1H), 2.82 (dd, J = 14.3, 8.2 Hz, 1H), 1.58 
(dt, J = 13.5, 6.6 Hz, 1H), 1.45 (t, J = 7.2 Hz, 2H), 1.23 (d, J = 7.2 Hz, 3H), 0.86 (dd, J = 
20.4, 6.6 Hz, 6H); 13C NMR (126 MHz, DMSO-d6) δ 174.4, 171.9, 169.6, 169.5, 168.6, 
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168.5, 156.8, 130.8, 124.8, 115.6, 113.1, 54.0, 52.5, 52.4, 51.1, 49.1, 41.7, 41.5, 41.4, 41.1, 
36.3, 35.6, 35.5, 24.5, 23.3, 21.8, 17.9; IR (KBr, cm-1) 3294(br), 3067(br), 2962(m), 
2159(w), 1676(s), 1518(s), 1431(w), 1205(m), 1136(m). 
 
Peptide 46.  Peptide 38 (3.2 mg, 3.8 µmol) was subjected to the general photochemical 
unstapling protocol to yield 3.0 mg (96%). HRMS Found (ES) m/z 820.3257 [(M+H)+; 
calcd for C34H50N11O9S2: 820.3234]; 
1H NMR (500 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.32 
(t, J = 5.6 Hz, 1H), 8.25 (d, J = 7.2 Hz, 1H), 8.22 (d, J = 5.7 Hz, 1H), 8.19 – 8.13 (m, 1H), 
7.80 (d, J = 8.3 Hz, 1H), 7.73 – 7.69 (m, 2H), 7.68 (d, J = 5.1 Hz, 1H), 7.29 (s, 1H), 7.02 
(d, J = 8.1 Hz, 2H), 6.98 (s, 1H), 6.69 (d, J = 8.1 Hz, 2H), 6.56 (s, 1H), 4.55 – 4.47 (m, 
1H), 4.44 (dd, J = 13.5, 8.1 Hz, 1H), 4.33 – 4.16 (m, 2H), 4.13 (t, J = 5.4 Hz, 1H), 3.83 
(dd, J = 16.6, 5.7 Hz, 1H), 3.79 – 3.68 (m, 4H), 3.13 – 2.99 (m, 3H), 2.93 (dd, J = 14.5, 4.7 
Hz, 1H), 2.82 – 2.65 (m, 1H), 2.21 – 2.10 (m, 1H), 2.10 – 2.04 (m, 1H), 2.04 – 1.92 (m, 
2H), 1.69 – 1.53 (m, 2H), 1.44 (dt, J = 9.2, 4.5 Hz, 2H), 1.39 – 1.31 (m, 1H), 1.21 (d, J = 
7.1 Hz, 3H), 0.87 (d, J = 6.3 Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, 
DMSO) δ 173.9, 171.6, 170.0, 169.1, 168.8, 168.8, 166.9, 156.3, 131.7, 131.5, 130.3, 
128.6, 115.2, 112.9, 112.8, 67.4, 50.9, 50.8, 48.4, 42.0, 41.9, 41.0, 38.1, 29.8, 29.8, 28.3, 
24.1, 23.2, 23.0, 22.3, 21.5, 17.6, 13.8, 10.8; IR (KBr, cm-1) 3409(br), 2928(w), 2159(w), 
1671(s), 1541(m), 1205(m), 1180(w), 1134(w).  
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Peptide 47.  Peptide 40 (4.0 mg, 2.3 µmol) was subjected to the general photochemical 
unstapling protocol to yield 3.9 mg (99%): MALDI-TOF Found m/z 1743.230 [(M+H)+; 
calcd for C81H123N20O19S2: 1743.871]; 
1H NMR (500 MHz, DMSO-d6) δ 9.21 (d, J = 12.0 
Hz, 1H), 8.57 (d, J = 7.4 Hz, 1H), 8.32 (d, J = 8.3 Hz, 1H), 8.23 – 8.17 (m, 1H), 8.15 (d, J 
= 7.8 Hz, 1H), 8.13 – 8.00 (m, 4H), 7.97 (d, J = 7.6 Hz, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.86 
(d, J = 7.7 Hz, 1H), 7.80 (s, 7H), 7.40 (s, 1H), 7.21 (d, J = 6.7 Hz, 3H), 7.16 (d, J = 6.3 Hz, 
1H), 7.07 (s, 1H), 7.02 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.2 Hz, 2H), 6.64 (d, J = 8.1 Hz, 
2H), 6.60 (d, J = 8.3 Hz, 2H), 5.42 (s, 1H), 5.22 – 5.14 (m, 1H), 5.01 (d, J = 4.0 Hz, 1H), 
4.66 – 4.57 (m, 3H), 4.55 (t, J = 7.0 Hz, 1H), 4.49 (d, J = 3.6 Hz, 1H), 4.44 (d, J = 6.6 Hz, 
1H), 4.43 – 4.38 (m, 1H), 4.37 – 4.24 (m, 3H), 4.23 – 4.17 (m, 1H), 4.17 – 4.09 (m, 1H), 
4.03 (q, J = 6.8 Hz, 1H), 3.98 – 3.90 (m, 1H), 3.81 – 3.68 (m, 2H), 3.15 (dd, J = 13.3, 8.7 
Hz, 1H), 3.07 (dd, J = 14.5, 3.3 Hz, 1H), 2.91 (d, J = 11.3 Hz, 1H), 2.83 (dd, J = 13.9, 9.1 
Hz, 1H), 2.75 (s, 6H), 2.65 – 2.62 (m, 1H), 1.78 – 1.39 (m, 17H), 1.31 (s, 5H), 1.23 (d, J = 
6.8 Hz, 3H), 1.05 (d, J = 6.3 Hz, 3H), 0.86 (t, J = 6.8 Hz, 5H), 0.84 – 0.73 (m, 11H); 13C 
NMR (126 MHz, DMSO) δ 176.4, 173.5, 171.8, 171.7, 171.6, 171.4, 171.3, 171.2, 170.6, 
169.7, 169.2, 168.7, 168.4, 167.9, 167.9, 155.9, 155.8, 137.4, 130.1, 130.1, 129.2, 128.0, 
127.7, 127.4, 126.3, 114.9, 114.9, 72.5, 67.0, 65.8, 63.1, 57.9, 56.3, 54.6, 53.6, 52.6, 52.6, 
52.3, 52.3, 52.3, 52.2, 52.2, 52.1, 51.2, 51.2, 51.2, 51.1, 49.8, 38.7, 36.3, 31.5, 26.7, 26.6, 
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24.1, 23.9, 23.2, 23.1, 22.3, 22.2, 21.7, 21.6, 20.5, 19.4, 14.5, 11.1; IR (KBr, cm-1) 
3298(br), 3071(br), 2962(m), 2933(m), 2159(w), 1671(s), 1517(m), 1438(m), 1203(s), 
1137(m). 
 
Peptide 48.  Peptide 42 (8.3 mg, 5.1 µmol) was subjected to the general photochemical 
unstapling protocol, without sparging with oxygen gas (atmospheric oxygen was not ex-
cluded). The crude reaction mixture was purified by reverse-phase HPLC (gradient 10-
60% organic over 15 min) to yield 2.1 mg (38%) of a white powder after lyophilization. 
MALDI-TOF m/z 1689.333 [(M+H)+; calcd for C78H105N20O19S2: 1689.730]; 
1H NMR 
(500 MHz, DMSO-d6) δ 10.77 (s, 1H), 8.67 (t, J = 5.7 Hz, 1H), 8.48 (d, J = 8.0 Hz, 1H), 
8.34 (d, J = 8.0 Hz, 1H), 8.21 – 8.01 (m, 6H), 8.01 – 7.86 (m, 5H), 7.86 – 7.65 (m, 6H), 
7.61 (d, J = 7.9 Hz, 1H), 7.50 – 7.41 (m, 2H), 7.32 (d, J = 7.9 Hz, 1H), 7.27 – 7.08 (m, 
15H), 7.05 (t, J = 7.5 Hz, 1H), 7.00 (d, J = 9.7 Hz, 1H), 6.97 (d, J = 7.4 Hz, 1H), 4.88 (d, 
J = 4.5 Hz, 1H), 4.72 – 4.60 (m, 1H), 4.57 (d, J = 5.8 Hz, 1H), 4.54 – 4.42 (m, 2H), 4.42 – 
4.26 (m, 4H), 4.21 (dd, J = 8.6, 3.9 Hz, 2H), 4.10 – 3.93 (m, 1H), 3.94 – 3.82 (m, 3H), 3.74 
– 3.57 (m, 1H), 3.53 – 3.43 (m, 1H), 3.19 (dd, J = 13.7, 8.8 Hz, 2H), 3.14 – 3.06 (m, 1H), 
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3.03 – 2.95 (m, 2H), 2.94 – 2.88 (m, 1H), 2.88 – 2.76 (m, 2H), 2.71 (t, J = 7.3 Hz, 4H), 
2.41 – 2.32 (m, 1H), 1.71 – 1.60 (m, 1H), 1.58 – 1.41 (m, 7H), 1.36 (d, J = 6.9 Hz, 3H), 
1.32 – 1.18 (m, 5H), 1.14 (d, J = 6.9 Hz, 1H), 1.04 (d, J = 6.2 Hz, 3H), 0.97 (d, J = 6.4 Hz, 
3H); 13C NMR (126 MHz, DMSO) δ 171.8, 171.3, 171.2, 170.9, 170.8, 170.8, 170.6, 170.5, 
170.3, 170.1, 169.8, 169.7, 169.7, 168.6, 168.4, 137.7, 137.6, 137.5, 136.0, 129.2, 129.2, 
129.0, 128.0, 127.9, 127.3, 126.1, 126.1, 123.6, 120.8, 118.5, 118.4, 118.2, 116.1, 112.9, 
111.2, 109.8, 70.5, 70.4, 66.6, 61.4, 57.9, 57.8, 54.1, 53.9, 53.7, 53.3, 53.3, 52.5, 52.3, 52.3, 
49.5, 48.1, 41.8, 38.7, 37.3, 37.3, 37.2, 37.2, 37.2, 37.0, 35.6, 31.1, 26.6, 26.6, 22.1, 22.1, 
19.3, 19.3, 17.1; IR (KBr, cm-1) 3424(br), 2933(w), 2159(w), 1671(s), 1632(s), 1526(m), 
1204(w), 1136(w).  
General Procedure for Nitrile Removal from the Thiocyanates 
 
A 13 mm test tube was charged with peptide 3 (1-5 mg) and dissolved in water (1.0 mL). 
To this solution was added 4 equivalents of a pre-mixed 250 mM solution of sodium cys-
teine [prepared by dissolving cysteine (121 mg, 1.0 mmol) in 0.25M NaOH (4 mL, 1 
equiv)]. The contents were stirred for 1 hour, then formic acid (4-8 equiv) was added and 
the reaction solution was purified by reverse-phase high-pressure liquid chromatography 
(HPLC) to yield peptide 1 as a white lyophilized powder and 4 was also separated from the 
reaction. 
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Regeneration of 32. Peptide 34 (6.2 mg, 10.0 μmol) was subjected to the general nitrile 
removal protocol then purified by reverse-phase HPLC (5 - 15% organic over 5 min) to 
yield 4.9 mg (87%) of peptide 32 as a white lyophilized powder and 1.3 mg (45%) 35 is 
also separated from the reaction. Spectral data was identical to 32 prepared by SPPS. 
 
(R)-2-amino-4,5-dihydrothiazole-4-carboxylic acid (35): HRMS Found (ES) m/z 
147.0228 [(M+H)+; calcd for C4H6N2O2S: 147.0228]; 
1H NMR (500 MHz, Deuterium Ox-
ide) δ 4.75 (dd, J = 8.8, 5.0 Hz, 1H), 3.92 (dd, J = 11.3, 8.9 Hz, 1H), 3.69 (dd, J = 11.4, 5.0 
Hz, 1H); 13C NMR (126 MHz, Deuterium Oxide) δ 175.5, 173.9, 63.8, 34.7; IR (KBr, cm-
1) 3153(br), 2980(br), 22840(br), 2347(m), 2281(m), 2222(m), 1638(s), 1588(s), 1442(m), 
1392(s), 1290(m).  
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Regeneration of SI-4. Peptide 44 (1.1 mg, 1.7 μmol) was subjected to the general nitrile 
removal protocol then purified by reverse-phase HPLC (5 - 35% organic over 12 min) to 
yield 0.7 mg (68%) of peptide SI-4 as a white lyophilized powder. Spectral data was iden-
tical to SI-4 prepared by SPPS. 
 
Regeneration of SI-5. Peptide 45 (1.5 mg, 1.9 μmol) was subjected to the general nitrile 
removal protocol then purified by reverse-phase HPLC (5 - 60% organic over 12 min) to 
yield 1.1 mg (78%) of peptide SI-5 as a white lyophilized powder. Spectral data was iden-
tical to SI-5 prepared by SPPS. 
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Regeneration of SI-6. Peptide 46 (5.0 mg, 6.1 μmol) was subjected to the general nitrile 
removal protocol then purified by reverse-phase HPLC (5 - 60% organic over 12 min) to 
yield 2.7 mg (58%) of peptide SI-6 as a white lyophilized powder. Spectral data was iden-
tical to SI-6 prepared by SPPS. 
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Regeneration of SI-8. Peptide 3e (1.7 mg, 1.0 μmol) was subjected to the general nitrile 
removal protocol then purified by reverse-phase HPLC [eluent water/MeCN/AcOH 
(85:10:5) and MeCN (organic) buffered with 0.1%TFA] (5 - 40% organic over 15 min) to 
yield 0.9 mg (55%) of peptide SI-8 as a white lyophilized powder. Spectral data was iden-
tical to SI-8 prepared by SPPS. 
 
Regeneration of SI-10. Peptide 48 (3.2 mg, 1.9 μmol) was subjected to the general nitrile 
removal protocol then purified by reverse-phase HPLC (10 - 60% organic over 15 min) to 
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yield 2.1 mg (68%) of peptide SI-10 as a white lyophilized powder. Spectral data was 
identical to SI-10 prepared by SPPS. 
 
Peptide 49. Constructed by SPPS from 0.20 mmol loaded Rink amide resin. Removal of 
the peptide from resin was conducted with cocktail B following the general cleavage 
method. The peptide was purified by reverse-phase HPLC (5 - 40% organic over 12 min) 
and exchanged with 0.1 M HCl to give 27.3 mg (42% • HCl salt form) of a white amor-
phous powder after lyophilization: HRMS (ES) Found m/z 291.3893 [(M+H)+; calcd for 
C11H23N4O3S: 291.3895]. 
 
Peptide 50. A 50 mL plastic Flacon tube was charged with peptide 49 (13.7 mg, 0.042 
mmol) and dissolved in 10 mM monosodium phosphate buffer (50 mL). To a separate 250 
mL round bottom flask was added dichlorotetrazine (19 mg, 0.126 mmol, 3 equiv.) and 
dissolved in acetonitrile (25 mL). To the solution of dichlorotetrazine was added 10 mM 
monosodium phosphate buffer (25 mL) immediately followed by the solution of peptide 
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49 and the contents were stirred for one minute. The reaction solution was frozen in dry 
ice/acetone bath and lyophilized. The crude product was purified by reverse-phase HPLC 
(5 - 45% organic over 12 min) and exchanged with 0.1 M HCl to give 13.2 mg (71% • HCl 
salt form) of 50 as an orange amorphous powder after lyophilization. HRMS (ES) Found 
m/z 405.1217 [(M+H)+; calcd for C13H22ClN8O3S: 405.1219]; 
1H NMR (500 MHz, DMSO-
d6) δ 8.39 (d, J = 8.0 Hz, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.74 (s, 3H), 7.31 (s, 1H), 7.06 (s, 
1H), 4.70 (q, J = 7.3 Hz, 1H), 4.18 (td, J = 8.5, 4.9 Hz, 2H), 3.78 (dd, J = 13.5, 5.7 Hz, 
1H), 3.53 (dd, J = 13.5, 7.6 Hz, 1H), 2.75 (d, J = 6.3 Hz, 2H), 1.86 (s, 3H), 1.75 – 1.64 (m, 
1H), 1.52 (ddd, J = 12.6, 8.8, 5.1 Hz, 4H), 1.38 – 1.21 (m, 2H). 13C NMR (126 MHz, 
DMSO) δ 174.7, 173.0, 169.8, 169.2, 164.9, 52.3, 51.3, 32.0, 31.2, 26.6, 22.4, 22.1. 
 
Peptide 51. A 250 mL round bottom flask was charged with peptide 50 (9.6 mg, 0.022 
mmol) dissolved in 1 mM monosodium phosphate (40 mL) pH ~5. With vigorous stirring 
of the solution containing peptide 50 was added 500 mM disodium phosphate (5 mL) to 
change the pH to ~8.5 and stirring continued for five minutes. Next, 1M HCl (2.2 mL) was 
added to adjust to pH 6, followed by the addition of MeCN (0.5 mL). The solution was 
divided into two parts. The solution was transferred to a gravity C18-silica-gel 25 gram 
column, preequilibrated with water/MeCN (99:1) and 0.1%TFA. The solution was allowed 
to drain and flushed with water/MeCN (99:1) and 0.1%TFA to remove most of the salts. 
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The product can be visualized by the red color and was collected by eluting with wa-
ter/MeCN (1:1) and 0.1%TFA. After all the red material was collected, the column was 
then equilibrated back to water/MeCN (99:1) and 0.1%TFA and repeated for the other 
fraction. The fractions containing the product were condensed in vacuo to remove the 
MeCN and lyophilized. The remaining product was purified by reverse-phase HPLC (10 - 
60% organic over 12 min) and exchanged with 0.1 M HCl to give 6.7 mg (83%) of 51 as 
an orange amorphous powder after lyophilization. HRMS (ES) Found m/z 369.1451 
[(M+H)+; calcd for C13H21N8O3S: 369.1452]. 
1H NMR (500 MHz, DMSO-d6) δ 8.40 (t, J 
= 6.6 Hz, 1H), 8.22 (d, J = 8.6 Hz, 1H), 7.31 (s, 1H), 7.18 (d, J = 7.5 Hz, 1H), 7.04 (s, 1H), 
4.46 (t, J = 8.9 Hz, 1H), 4.05 (dd, J = 11.7, 5.5 Hz, 1H), 3.92 (d, J = 14.8 Hz, 1H), 3.78 – 
3.63 (m, 1H), 3.55 – 3.43 (m, 1H), 3.38 (dd, J = 14.8, 9.4 Hz, 1H), 1.88 – 1.74 (m, 1H), 
1.65 – 1.54 (m, 1H), 1.54 – 1.44 (m, 1H), 1.40 – 1.29 (m, 1H), 1.11 – 0.96 (m, 2H). 13C 
NMR (126 MHz, DMSO) δ 172.7, 169.5, 169.1, 162.3, 160.3, 51.9, 51.6, 37.4, 31.4, 31.2, 
29.1, 22.6, 20.5. 
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Synthesis of Bicyclononyne Tethered to a Fluorescein Dye 
Compounds SI-12 and SI-13 were prepared according to the following procedures. 
5-((2-aminoethyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (SI-
12): Gasparini, G.; Bang, E. K.; Molinard, G.; Tulumello, D. V.; Ward, S.; Kelley, S. O.; 
Roux, A.; Sakai, N.; Matile, S. J. Am. Chem. Soc. 2014, 136, 6069 – 6074. 
(1R,8S,9r)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl (4-nitrophenyl) carbonate (SI-13): 
Schieber, C.; Bestetti, A.; Lim, J. P.; Ryan, Anneke D.; Nguyen, T. L.; Eldridge, R.; White, 
A. R.; Gleeson, P. A.; Donnelly, P. S.; Williams, S. J.; Mulvaney, P. Angew. Chem. Int. 
Ed. 2012 ,  51, 10523 – 10527. 
 
Compound 54. To a 5 mL round bottom flask containing 5-((2-aminoethyl)carbamoyl)-2-
(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (9.0 mg, 22 μmol) dissolved in MeCN 
(500 μL) was added bicyclo[6.1.0]non-4-yn-9-ylmethyl (4-nitrophenyl) carbonate (8.3 mg, 
26 μmol, 1.2 equiv) in MeCN (250 μL) followed by the addition of pyridine (16 μL, 200 
μmol, 10 equiv) and DMAP (2.7 mg, 22 μmol, 1 equiv). The contents were then stirred at 
35ºC for 48 hours. The reaction mixture was evaporated and the crude re-dissolved in wa-
ter/MeCN (7:3, 1000 μL) and purified by reverse-phase HPLC (gradient 10-80% organic 
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over 15 minutes) to give 8.2 mg (63%) after lyophilization. HRMS (ES) m/z 595.2069 
[(M+H)+; calcd for C34H31N2O8: 595.2080]. 
1H NMR (500 MHz, Methanol-d4) δ 8.49 (s, 
1H), 8.21 (d, J = 8.0 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 6.79 (s, 2H), 6.73 (d, J = 8.3 Hz, 
2H), 6.64 (d, J = 8.8 Hz, 2H), 4.15 (d, J = 8.2 Hz, 2H), 3.54 (t, J = 5.7 Hz, 2H), 3.39 (t, J 
= 6.0 Hz, 2H), 2.19 (d, J = 12.8 Hz, 4H), 2.09 (d, J = 15.3 Hz, 2H), 1.56 (dd, J = 21.8, 9.7 
Hz, 2H), 1.36 (dt, J = 17.3, 8.6 Hz, 1H), 0.87 (t, J = 10.0 Hz, 2H). 
Bioconjugation of 54 with s-Tetrazine Peptide 42 
 
Compound 55.   To a 5 mL round bottom flask was added a solution (1.1 mM) of peptide 
42 dissolved in water (500 μL) followed by a solution (1.2 mM) of bicyclononyne 54 in 
DMSO (500 μL). The contents were stirred at room temperature for 4 days and the solvent 
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removed in vacuo. The residue was purified by reverse-phase HPLC (gradient 10-60% or-
ganic over 15 min) to give (0.9 mg, 68%) of a yellow-orange powder after lyophilization. 
MALDI-TOF m/z 2283.468 [(M+H)+; calcd for C112H135N22O27S2: 2283.930]. 
 
Tetrazine Stapling of the Thioredoxin Protein 
 
To a 1.7 mL mini-centrifuge tube containing thioredoxin (0.25 mg, 21 nmol) dissolved in 
acetate buffer pH 5 (200 mM, 100 μL), was added TCEP immobilized on agrose (300 μL, 
8 μmol/mL, 2.4 μmol, 112 equiv); the final buffer concentration was 50 mM. The reaction 
was stirred at room temperature for 2.0 hours under an argon atmosphere. The contents 
were kept under a blanket of argon, then filtered through a plastic pipet tip with a cotton 
plug and rinsed with degassed 50 mM acetate buffer pH 5 (3 ⨯ 200 μL). To the pooled 
filtrates (1.0 mL) in a 1.7 mL mini-centrifuge tube was added a pre-mixed solution of di-
chlorotetrazine in DMSO (20 μL, 87 nmol, 4 equiv, [0.67 mg/mL]) and stirred for 1 minute. 
The solution was then transferred to a pre-equilibrated disposable PD-10 desalting column 
and eluted with 50 mM Tris, pH 7.8, 150 mM NaCl. The fractions containing protein were 
pooled and stored at 4ºC. Bradford assay (88% yield). MALDI-TOF m/z 11757.782 
Native-Trx 56
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[(M+H)+; 11756.45; calculated for Trx-1 (11675.43 Da) + tetrazine (80.01 Da) + H+ 
(1.01)]. 
Photochemical Unstapling and Regeneration of the Thioredoxin Protein 
 
Sample Preparation for Comparison 
A sample of tetrazine thioredoxin (0.1 mg, 8 nmol), from the desalting column in 50 mM 
Tris, pH 7.8, 150 mM NaCl (1000 μL) was divided between two 1.7 mL mini-centrifuge 
tubes. One sample underwent photolysis and the other used as a comparsion.  
Tetrazine Thioredoxin Photolysis 
A 1.7 mL mini-centrifuge tube containing tetrazine thioredoxin (0.05 mg, 4 nmol) dis-
solved in 50 mM Tris, pH 7.8, 150 mM NaCl (500 μL) was suspended in a Rayonet® pho-
toreactor equipped with three UV-B lamps. The contents were irradiated for 1.0 hour, 
MALDI indicated consumption of the starting material with partial loss of the nitrile 
groups. 
 
 
56 57
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Regeneration of the Protein 
To the photolyzed sample dissolved in 50 mM Tris, pH 7.8, 150 mM NaCl (500 μL), was 
added cysteine (25 μL) of a 20 mM solution in the Tris buffer system and TCEP (25 μL) 
of a 20 mM solution in the Tris buffer system. The contents were allowed to stand for 4.0 
hours and then diluted to 3 mL with the Tris buffer system and transferred for centrifuga-
tion in an Amicon centrifugal filter (MWCO 3000, 35º fixed angle rotor @ 7000⨯G, 30 
minutes, 4ºC), the concentrated sample (150 μL) was diluted to 3 mL and repeated. The 
retenate was collected and diluted to 500μL with the Tris buffer system, then Ellman’s 
reagent [5,5'-dithio-bis-(2-nitrobenzoic acid)] (25 μL of a 20 mM solution in the Tris buffer 
system) was added and allowed to stand for 6.0 hours. The contents were then diluted to 3 
mL with the Tris buffer system and transferred for centrifugation in an Amicon centrifugal 
filter (MWCO 3000, 35º fixed angle rotor @ 7000⨯G, 30 minutes, 4ºC). The retenate was 
collected and diluted to 500 μL with the Tris buffer solution and analyzed by MALDI-TOF 
and FPLC. Bradford assay (73% yield).  MALDI-TOF m/z 11676.188 [(M+H)+; 11676.44]. 
Measurement of Regenerated Thioredoxin Bioactivity 
 
Thioredoxin activity was measured by following the reduction of insulin described by the 
method of Xianqin Yang and Kesen Ma, Journal of Bacteriology, 2010, 192(5), 1370–
1376. 
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The standard thioredoxin assay mixture, prepared in 200 μL overall volume, contained 50 
mM sodium phosphate buffer, pH 7.0, 1 mM EDTA,  0.15 mM human insulin, 1 mM 
dithiothreitol. The amounts of native thioredoxin E. coli, tetrazine thioredoxin, and regen-
erated thioredoxin were varied, concentrations of protein were determined by Bradford 
assay. Sample were run in duplicate, the increase in turbity from the reduction of insulin 
was monitored at 650 nm at 30°C by a Tecan plate reader. 
 
The kinetic curves were baseline corrected by subtracting from insulin reduction by dithi-
othreitol alone. The corrected slopes from the kinetic data (ΔmAU/min), in the linear re-
gion, were plotted as a function of concentration of protein. 
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Control Experiment for the Photolysis of Native Thioredoxin 
 
A 1.7 mL mini-centrifuge tube containing native thioredoxin (0.05 mg, 4 nmol) dissolved 
in 50 mM Tris, pH 7.8, 150 mM NaCl (500 μL) was suspended in a Rayonet® photoreactor 
equipped with three UV-B lamps. The contents were irradiated for 1.0 hour, MALDI indi-
cated no change in the mass after photolysis. The native thioredoxin and the product from 
photolysis were analyzed by the insulin reduction bioassay described previously. The prod-
uct from photolysis showed a significant decrease in activity when compared to the activity 
of the native protein. 
Photochemical Unstapling of 56 with Nd:YAG Flashlamp at 355 nm 
 
To a 3 mL quartz cuvette was added tetrazine thioredoxin 56 (0.23 mg, 20 nmol) dissolved 
in 10 mM PBS, pH 7.0, 100 mM NaCl (2000 μL) overall concentration of protein 10μM 
57Native-Trx
56 57
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and then transferred to a laser setup consisting of a Nd:YAG laser with a 355 nm wave-
length. The contents were irradiated for 1.0 hour. MALDI indicated consumption of the 
starting material. The reaction solution was then treated with 10 mM cysteine in 500 mM 
phosphate buffer system (pH 7.8) to achieve a 1 mM overall concentration of cysteine and 
a 9 μM concentration for the protein which was allowed to stand at 5ºC for 16 hours. The 
reaction solution was then removed by centrifugal filtration and analyzed by MALDI-TOF-
MS to find both the loss of the nitriles from the thiocyanates and the molecular mass of 
regenerated thioredoxin protein. MALDI-TOF m/z 11676.188 [(M+H)+; 11676.44]. 
Bioactivity Measurement for Thioredoxin Resulting from the Flashlamp Conditions 
 
The standard thioredoxin assay mixture, prepared in 200 μL overall volume, contained 50 
mM sodium phosphate buffer, pH 7.0, 1 mM EDTA,  0.15 mM human insulin, 1 mM 
dithiothreitol. The amounts of native thioredoxin E. coli, tetrazine thioredoxin, and regen-
erated thioredoxin were varied, concentrations of protein were determined by Bradford 
assay. Sample were run in triplicate, the increase in turbity from the reduction of insulin 
was monitored at 650 nm at 30°C by a Tecan plate reader. 
 
121 
 
 
Inverse-Electron Demand Diels-Alder Reaction of Bicyclononyne with Tetrazine 
Thioredoxin 
 
To a 1.7 mL mini-centrifuge tube containing tetrazine thioredoxin (0.05 mg, 4 nmol) dis-
solved in 50 mM Tris, pH 7.8, 150 mM NaCl (500 μL) was added a solution of 5  (100 μL, 
0.024 mg, 40 nmol, 10 equiv) dissolved in the Tris buffer system. The contents were al-
lowed to stand at ambient temperature for 10 days. The contents were next transferred for 
centrifugation in an Amicon centrifugal filter (MWCO 3000, 35º fixed angle rotor @ 
7000⨯G, 30 minutes, 4ºC), the concentrated sample (150 μL) was diluted to 3 mL with the 
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Tris buffer and repeated. The reaction was monitored by mass spectrometry, which illus-
trated the loss of nitrogen and an additional mass equal to 5 . MALDI-TOF m/z 12323.622 
[(M+H)+; 12322.64; calculated for tetrazine Trx (11755.44) + 5 (594.20 Da) + H+ (1.01) – 
N2 (28.01)].  
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APPENDIX 
 
Relevant Spectra 
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